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A B S T R A C T
Background
People experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharma-
cological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries.
Objectives
To estimate the effects of droperidol, including its cost-effectiveness, when compared to placebo, other ’standard’ or ’non-standard’
treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic
symptoms in people with schizophrenia-like illnesses.
Search methods
Weupdated previous searches by searching theCochrane Schizophrenia Group Register (18 December 2015). We searched references of
all identified studies for further trial citations and contacted authors of trials.We supplemented these electronic searches by handsearching
reference lists and contacting both the pharmaceutical industry and relevant authors.
Selection criteria
We included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people
acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, themanic
phase of bipolar disorder or a brief psychotic episode.
Data collection and analysis
For included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were
lost to follow-up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence
intervals (CI). We created a ’Summary of findings’ table using GRADE.
Main results
We identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was
compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N
= 227, RR 1.18, 95% CI 1.05 to 1.31, high-quality evidence). There was a clear demonstration of reduced risk of needing additional
medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, high-quality evidence). There
was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, moderate-
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quality evidence) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, low-quality evidence) than
placebo. For ’being ready for discharge’, there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to
1.48, high-quality evidence). There were no data for mental state and costs.
Similarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence
of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, high-quality evidence). There was a clear demonstration of reduced
risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI
0.16 to 0.90, high-quality evidence). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228,
RR 2.80, 95% CI 0.30 to 26.49,moderate-quality evidence) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80,
95% CI 0.12 to 67.98, low-quality evidence) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental
state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of
Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI -0.07 to 0.29, low-quality evidence). There were no
data for service use and costs.
Whereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found
droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, high-quality evidence). As
regards the ’need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54,
95% CI 0.24 to 1.20, moderate-quality evidence). In terms of adverse effects, we found no statistically significant differences between the
two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, low-quality evidence) or respiratory hypoxia
(1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, moderate-quality evidence) - but use of midazolam did result in three people (out
of around 70) needing some sort of ’airway management’ with no such events in the droperidol group. There were no data for mental
state, service use and costs.
Furthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found
no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94
to 1.11, high-quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after
60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high-quality evidence). There was no
evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate-quality
evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low-quality evidence) than olanzapine.
For ’being ready for discharge’, there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high-quality
evidence). There were no data for mental state and costs.
Authors’ conclusions
Previously, the use of droperidol was justified based on experience rather than evidence from well-conducted and reported randomised
trials. However, this update found high-quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis.
Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of
serious mental illnesses.
P L A I N L A N G U A G E S U M M A R Y
Droperidol for psychosis-induced aggression or agitation
Is droperidol effective for managing people who are aggressive or agitated due to psychosis?
Background
People with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief
in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with
psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise)
people in this situation. Previously, the use of this drug was based on results from small clinical trials with no firm conclusion regarding
its effects. Larger trials were needed.
Searching
In 2015, the Information Specialist of the Cochrane Schizophrenia Group updated previous searches of their specialised register of
studies. The review authors identified and screened 21 records.
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Description of studies
Six randomised controlled studies are now included in the review. All the studies randomised people who were aggressive or agitated
due to psychosis to receive either droperidol or placebo (a pretend medicine), haloperidol, olanzapine or midazolam. The size of the
studies ranged from 40 to 221 participants. All took place in within a hospital. Four of the six studies were under two hours of duration.
Main results
Compared to placebo, droperidol was more effective at tranquillising agitated participants 30 minutes after taking it. Similar results
were found for tranquillisation when droperidol was compared with haloperidol but this effect was less clear, and not evident when
droperidol was compared to midazolam or olanzapine. Droperidol did not cause more side effects than the other drugs in the studies.
The studies did not look at costs.
Review authors’ conclusions
Although we could only include six studies, they provided high-quality evidence suggesting that droperidol is effective and can be used
to control people with very disturbed and aggressive behaviours caused by psychosis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Droperidol versus placebo
Patient or population: acute psychosis
Setting: inpat ient
Intervention: droperidol
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with droperidol
Tranquillisa-
t ion or asleep: tranquil-
lised/ sleep - by around
30 minutes
Moderate RR 1.18
(1.05 to 1.31)
227
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion800 per 1000 944 per 1000
(840 to 1000)
Global state: use of ad-
dit ional medicat ion - by
60 minutes af ter init ial
adequate sedat ion unt il
ED discharge (various
psychotropic drugs)
Moderate RR 0.55
(0.36 to 0.85)
227
(1 RCT)
⊕⊕⊕⊕
High 1,2
’Moderate’ control risk
approximately that of
trial populat ion
400 per 1000 220 per 1000
(144 to 340)
Adverse ef fects - car-
diovascular - arrhyth-
m ia
Moderate RR 0.34
(0.01 to 8.31)
227
(1 RCT)
⊕⊕⊕©
Moderate 1,3
’Moderate’ control risk
approximately that of
trial populat ion10 per 1000 3 per 1000
(0 to 83)
Adverse ef fects - respi-
ratory - airway obstruc-
t ion
Moderate RR 0.62
(0.15 to 2.52)
227
(1 RCT)
⊕⊕©©
Low 3,4
’Moderate’ control risk
approximately that of
trial populat ion40 per 1000 25 per 1000
(6 to 101)
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Service use: person
able to be discharged
home
Moderate RR 1.16
(0.90 to 1.48)
227
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion500 per 1000 580 per 1000
(450 to 740)
Mental state - improve-
ment
Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
Economic: direct costs Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ED: emergency department; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias: rated ’not serious’ (no downgrade) - clear report ing of good methods.
2 Indirectness: rated ’not serious’ (no downgrade) - but proxy outcome for ’Another episode of aggression by 24 hours’.
3 Imprecision: rated ’serious’ (downgraded by 1) - few events, wide conf idence intervals.
4 Indirectness: rated ’serious’ (downgraded by 1) - respiratory obstruct ion proxy measure - not ’death’.
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B A C K G R O U N D
Description of the condition
Violent or acutely disturbed people pose a risk to themselves and
to others, as well as a diagnostic dilemma (Thomas 1992). The ac-
tual prevalence of violent behaviour is high although percentages
differ according to setting, definition, client group and measure
(Latalova 2014). For people presenting with first episode of ill-
ness, serious violence has been reported in anything between 2%
and nearly 30% (Latalova 2014). Violent behaviour may be more
prevalent at this point in a person’s illness, when their symptoms
may have gone unnoticed for some time, and they are more vig-
orous than later on in life (Winsper 2013).
Ideally, to ensure a safe and therapeutic environment, attempts
should be made to calm the person either through verbal de-esca-
lation or intensive nursing techniques. Behaviour may frequently
be too disturbed or agitated for ’verbal tranquillisation’ to be ef-
fective, and further action, in the form of rapid tranquillisation,
may be necessary.
Description of the intervention
Various drug regimens are used in such emergency situations, and
clinical practice differs. One survey from the USA found that the
medical directors of 20 emergency rooms preferred drug manage-
ment for aggressive people to be a haloperidol-lorazepam mixture
(Table 1) (Binder 1999). In 1993, a similar survey of clinicians’
preferences in the UK found that chlorpromazine was the most
common choice (Cunnane 1994). Another survey of emergency
rooms in Rio de Janeiro found that a haloperidol-promethazine
mixture was commonly used for emergency intramuscular (IM)
sedation of severely agitated/aggressive people (70 to 100 people
with suspected psychotic illness per week per 3.5 million; Table
2) (Huf 2002). A survey of frequency of emergency prescribing
in a general psychiatric hospital in South London (UK) showed
that rapid medical tranquillisation was required 102 times in 160
days (Pilowsky 1992). Eight different drugs were used, amongst
which diazepam, haloperidol and droperidol were usedmost often
(Table 3).
Droperidol (marketed asDehydrobenzperidol,Dridol,Droleptan,
Droperidols, Inapsin, Inapsine, Leptanal comp, Leptofen, Paxical
or Sintodian) has beenwidely used in Europe by psychiatrists since
the 1960s for treating acute or chronic psychoses (Cocito 1970;
Resnick 1984). It inhibits the effects of dopamine. In the USA, it
is used primarily in conjunction with anaesthetics because of its
sedative and antiemetic properties (Resnick 1984). Reported ad-
vantages of droperidol over haloperidol (another inhibitor of the
effects of dopamine) include: a faster onset of action when given
IM, swifter elimination from the body and fewer adverse effects
(Richards 1998). The most commonly reported adverse effects for
droperidol include hypotension (abnormally low blood pressure)
and tachycardia (above normal heart rate). Other adverse effects
include restlessness, hyperactivity, anxiety and dysphoria (feeling
ill at ease). The frequency of adverse effects involving movement
disorders is reported to be 20% to 40% (Cocito 1970).Droperidol
has been associated only rarely with serious adverse effects such
as neuroleptic malignant syndrome (altered consciousness, mus-
cle rigidity and autonomic instability) and sudden death. Sud-
den death has been reported to be associated with high doses of
droperidol (25 mg or more) in people at risk for cardiac dysrhyth-
mia, such as people with severe electrolyte disturbances or alco-
hol withdrawal (RxList 2000). Droperidol should not be given to
people with severe depression as it may aggravate their symptoms
(Martindale 1982).
Following an extensive risk-benefit assessment requested by the
Medicines Control Agency, Janssen-Cilag, the pharmaceutical
company who market droperidol, concluded that the oral form
of droperidol should be discontinued and that the injectable form
would no longer be commercially viable. The Medical Director of
Janssen-Cilag told PharmaTimes (www.pharmatimes.co.uk/) that
the decision had been taken because many people who receive
droperidol also receive other medications that extend QT prolon-
gation, and are more likely to have background illnesses that may
exacerbate the problem. He added that the company intended to
implement a world-wide withdrawal of droperidol, and supplies
would stop entering the distribution chain at the end of March
2001. This seems not to have happened and droperidol has been
used for this and other purposes (Furyk 2015; Storrar 2014), and
research has continued. Some authoritative findings are not sup-
portive of the original decision regardingQTprolongation (Calver
2015), and call into question the original Food andDrugs Author-
ity decision and their decision-making process (Newman 2015).
How the intervention might work
Droperidol, 1-(1-3-(p-fluorobenzoyl)propyl-1,2,3,6-tetrahydro-
4-pyridyl)-2-benzimidazolinone, is a butyrophenone neuroleptic
drug (Figure 1). Butyrophenones inhibit the effects of dopamine
and resemble phenothiazines such as trifluoperazine. They have
fewer sedative and antimuscarinic effects than other phenothiazine
derived antipsychotic drugs, but exhibit more pronounced ad-
verse effects upon the extrapyramidal nerve system. Back inMarch
2000, the cost of medication with droperidol (Droleptan) in Great
Britain was GBP0.90 for a 2 mL amp injection, or GBP0.25 for a
10 mg tablet (BNF 2000). Droperidol may be taken orally (5 mg
to 20 mg repeated every four to six hours, as necessary) or as an
IM or intravenous (IV) injection (dosages: up to 10 mg repeated
every four to six hours for IM; and 5 mg to 15 mg repeated every
four to six hours for IV). The onset of action from injection is 3 to
10 minutes, although the peak effect may not be apparent for 30
minutes. The duration of sedation and tranquillisation may last
6Droperidol for psychosis-induced aggression or agitation (Review)
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for two to four hours, although alteration of alertness may persist
for up to 12 hours (RxList 2000).
Figure 1. Droperidol structure.
Why it is important to do this review
Droperidol is still in use.We think it is still being used in Australia,
Belgium, Brazil, Czech Republic, Denmark, Finland, Greece, In-
dia, Italy, Netherlands, New Zealand, South Africa, Spain, Swe-
den, Thailand, and the USA. It is of interest to researchers and
clinicians in the area of management of acute aggression. Previous
versions of this review are out of date (Cure 2001; Cure 2004),
and this review forms one of a family of related work (Table 4).
O B J E C T I V E S
To estimate the effects of droperidol, including its cost-effective-
ness, when compared to placebo, other ’standard’ or ’non-stan-
dard’ treatments, or other forms of management of psychotic ill-
ness, in controlling acutely disturbed behaviour and reducing psy-
chotic symptoms in people with schizophrenia-like illnesses.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). If a trial had
been described as ’double-blind’ but implied randomisation, we
would have included such trials in a sensitivity analysis (see
Sensitivity analysis). We excluded quasi-randomised studies, such
as those allocating by alternate days of the week.
Types of participants
Any people with acutely disturbed/aggressive/agitated behaviour
secondary to psychotic illnesses such as schizophrenia, schizoaffec-
tive disorder, mixed affective disorders, the manic phase of bipo-
lar disorder or a brief psychotic episode, irrespective of age and
sex. The definition of ’acute’ adopted for the purposes of this re-
view was determined by the statements and implications made by
the authors of the trials that the behavioural disturbances of the
participants were of sudden onset or extreme in nature, or both.
If trial participants were included who were not clearly acutely
disturbed, we analysed data together and separately to see what
effect the results had on the summated outcome. If there were
differences, we presented data separately. We only included trials
of people with organic illnesses or people abusing substances if
participants were exhibiting disturbed behaviour resulting from a
psychotic episode, and we analysed these data separately. For the
2015 update, we decided to slightly widen our inclusion criteria
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by including studies where the majority of people in the study had
some form of mental illness that was thought to be fuelling their
aggression/agitation - even if their data were ’contaminated’ by
data relating to people who were aggressive for reasons thought to
not be because of mental illness.
Types of interventions
1 Droperidol
Any dose, given orally, or by IM or IV injection
Compared with:
a. Standard medication
Drug treatments that fit with normal ’custom and practice’: this
may have involved increasing the dose of standard medication
or addition of another ’standard’ psychotropic drug, such as an
antipsychotic, an anxiolytic (benzodiazepine or other) or a mood
stabiliser.Weproposed to report the effects of separate preparations
distinctly.
b. Non-standard medication
Drug treatments that were evaluated as a new type of interven-
tion. We proposed to report the effects of separate preparations
distinctly.
c. Placebo
d. Any other means of management
Types of outcome measures
We planned to divide outcomes into immediate (within two
hours), short term (longer than two hours to 24 hours), medium
term (longer than 24 hours to two weeks) and long term (beyond
two weeks).
Primary outcomes
1. Tranquilisation or asleep: tranquillised/sleep - by up to 30
minutes
2. Specific behaviours: aggression - another episode of
aggression by 24 hours
3. Adverse effect: specific and serious adverse effects by 24
hours
Secondary outcomes
1. Tranquillisation or asleep
1.1 Tranquil/asleep - after 30 minutes
1.2 Time to tranquillisation/sleep.
2. Specific behaviours
2.1 Self-harm, including suicide.
2.2 Injury to others.
2.3 Aggression.
2.3.1 Clinically important change in aggression.
2.3.2 Any change in aggression.
2.3.3 Average endpoint aggression score.
2.3.4 Average change in aggression scores.
3. Global state
3.1 Overall improvement.
3.2 Use of additional medication.
3.3 Use of restraints/seclusion.
3.4 Relapse - as defined by each study.
3.5 Recurrence of violent incidents.
3.6 Needing extra visits from the doctor.
3.7 Refusing oral medication.
3.8 Accepting treatment.
3.9 Average endpoint acceptance score.
3.10 Average change in acceptance score.
4. Adverse effects
4.1 Death.
4.2 Other clinically important general adverse effects.
4.3 Any general adverse effects.
4.4 Any serious, specific adverse effects - after 24 hours.
4.5 Average endpoint general adverse effect score.
4.6 Average change in general adverse effect scores.
4.7 Clinically important change in specific adverse effects.
4.8 Any change in specific adverse effects.
4.9 Average endpoint-specific adverse effects.
4.10 Average change in specific adverse effects.
5. Service outcomes
5.1 Duration of hospital stay.
5.2 Re-admission.
5.3 No clinically important engagement with services.
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5.4 Not any engagement with services.
5.5 Average endpoint engagement score.
5.6 Average change in engagement scores.
6. Mental state
6.1 Clinically important change in general mental state.
6.2 Any change in general mental state.
6.3 Average endpoint general mental state score.
6.4 Average change in general mental state scores.
7. Leaving the study early
7.1 For specific reasons.
7.2 For general reasons.
8. Satisfaction with treatment
8.1 Recipient of treatment not satisfied with treatment.
8.2 Recipient of treatment average satisfaction score.
8.3 Recipient of treatment average change in satisfaction scores.
8.4 Informal treatment provider not satisfied with treatment.
8.5 Informal treatment providers’ average satisfaction score.
8.6 Informal treatment providers’ average change in satisfaction
scores.
8.7 Professional providers not satisfied with treatment.
8.8 Professional providers’ average satisfaction score.
8.9 Professional providers’ average change in satisfaction scores.
9. Acceptance of treatment
9.1 Accepting treatment.
9.2 Average endpoint acceptance score.
9.3 Average change in acceptance score.
10. Quality of life
10.1 Clinically important change in quality of life.
10.2 Any change in quality of life.
10.3 Average endpoint quality of life score.
10.4 Average change in quality of life scores.
10.5 Clinically important change in specific aspects of quality of
life.
10.6 Any change in specific aspects of quality of life.
10.7 Average endpoint-specific aspects of quality of life.
10.8 Average change in specific aspects of quality of life.
11. Economic outcomes
11.1 Direct costs.
11.2 Indirect costs.
’Summary of findings’ table
Weused the GRADE approach to interpret findings (Schnemann
2008), and GRADE profiler (GRADEpro) to import data from
ReviewManager 5 (Review Manager) to create ’Summary of find-
ings’ tables. These tables provide outcome-specific information
concerning the overall quality of evidence from each included
study in the comparison, the magnitude of effect of the interven-
tions examined and the sum of available data on all outcomes that
we rated as important to patient care and decision making. We
aimed to select the following main outcomes for inclusion in the
’Summary of findings’ tables.
• Tranquillisation or asleep: tranquillised/sleep - by up to 30
minutes.
• Specific behaviours: aggression - another episode of
aggression - by 24 hours.
• Adverse effect - specific and serious adverse effects by 24
hours (not death).
• Adverse effect - specific and serious adverse effects (death).
• Service outcome - satisfaction with treatment (not
discharged).
• Mental state - improvement.
• Economic outcomes - direct costs.
Search methods for identification of studies
Electronic searches
On 18 December 2015, we searched the Cochrane Schizophrenia
Group’s Register of Trials using the following search string:
*Droperidol* in Intervention Field of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonym keywords and relevant studies because all
the studies have already been organised based on their interven-
tions and linked to the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature and conference proceedings (see Group’s
Module). The register as no language, date, document type or
publication status limitations for inclusion of records.
For previous searches, see Appendix 1.
Searching other resources
1 Reference searching
We inspected references of all included studies for further relevant
studies.
9Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 Personal contact
We contacted the first author of each included study for informa-
tion regarding unpublished trials.
Data collection and analysis
For previous data collection and analysis see Appendix 2.
Selection of studies
Review authors (MAK) and CEA (see Acknowledgements) inde-
pendently inspected citations from the 2015 search and identi-
fied relevant abstracts. We compared findings to ensure reliability.
In case of disputes, we would have acquired the full report for
more detailed scrutiny. One review author (MAK) obtained and
inspected full reports of the abstracts meeting the review criteria,
which CEA re-inspected to ensure a reliable selection. We did not
disagree on selection. In future versions, if it is not possible to re-
solve disagreements by discussion, we will attempt to contact the
study authors for clarification.
Data extraction and management
1 Extraction
Review author (MAK) independently extracted data from all in-
cluded studies and CA independently extracted data from a ran-
dom 20% sample. We discussed any disagreements and docu-
mented decisions; if necessary, we contacted authors of studies for
clarification. We extracted data presented only in graphs and fig-
ures whenever possible, but included these data in the review only
if two review authors independently had the same result. We at-
tempted to contact authors through an open-ended request to ob-
tain missing information or for clarification whenever necessary.
If studies were multicentre, we would have extracted data relevant
to each component centre separately.Where possible, we reported
total end-scale measures, as opposed to subscale measures.
2 Management
2.1 Forms
We extracted data onto simple standard forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
were described in a peer-reviewed journal (Marshall 2000); and
• the measuring instrument had not been written or modified
by one of the trialists for that trial.
Ideally, the measuring instrument should have been either a self-
report or completed by an independent rater or relative (not the
therapist). We realise that this is not often reported clearly; in
Description of studies we noted if this was the case.
2.3 Endpoint versus change data
Both endpoint and change data have advantages. Change data
can remove a component of between-person variability from the
analysis. However, calculation of change needs two assessments
(baseline and endpoint), which can be difficult in unstable and
difficult-to-measure conditions such as schizophrenia.We decided
to use primarily endpoint data, and only use change data if the
former were not available. We combined endpoint and change
data in the analysis, as we preferred to use mean differences (MD)
rather than standardised mean differences throughout (Higgins
2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards
to all data before inclusion.
For change data
• We entered change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether data are
skewed or not. We presented and entered change data into
statistical analyses.
For endpoint data
• When a scale started from the finite number 0, we
subtracted the lowest possible value from the mean and divided
this by the standard deviation (SD). If this value was lower than
1, it strongly suggested a skew, and we would have excluded the
study. If this ratio was higher than 1 but below 2, there was
suggestion of skew. We would have entered the study and tested
whether its inclusion or exclusion would have changed the
results substantially. Finally, if the ratio was larger than 2, we
would have included the study, because skew was less likely
(Altman 1996; Higgins 2011).
• If a scale started from a positive value (such as the Positive
and Negative Syndrome Scale, which can have values from 30 to
210) (Kay 1986), we would have modified the calculation
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described above to take into account the scale starting point. In
such cases, skew is present if 2 SD > (S - Smin), where S is the
mean score and Smin is the minimum score.
(Please note, irrespective of the above rules, we would enter end-
point data from studies of at least 200 participants in the analysis
because skewed data pose less of a problem in large studies.)
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that could be reported in different metrics, such as days
in hospital (e.g. mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary data
Where possible, we attempted to convert outcome measures to
dichotomous data. We did this by identifying cutoff points on
rating scales and dividing participants accordingly into ’clinically
improved’ or ’not clinically improved’. It is generally assumed that
if there is a 50% reduction in a scale-derived score such as the Brief
Psychiatric Rating Scale (BPRS), in Overall 1962, or the Positive
and Negative Syndrome Scale, in Kay 1986, this could be consid-
ered to be a clinically significant response (Leucht 2005a; Leucht
2005b). If data based on these thresholds were not available, we
used the primary cutoff presented by the original authors.
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
droperidol intervention. Where keeping to this made it impossible
to avoid outcome titles with clumsy double-negatives (e.g. ’not un-
improved’), we reported data where the left of the line indicated
an unfavourable outcome. We noted this in the relevant graphs.
Assessment of risk of bias in included studies
One review author (MAK) assessed risk of bias by using criteria
described in theCochrane Handbook for Systematic Reviews of Inter-
ventions to assess trial quality (Higgins 2011). This set of criteria
is based on evidence of associations between overestimate of effect
and high risk of bias of the article such as sequence generation,
allocation concealment, blinding, incomplete outcome data and
selective reporting.
Where a study provided inadequate details of randomisation and
other characteristics of the trial, she attempted to contact the study
authors to obtain further information.
We noted the level of risk of bias in both the text of the review and
in the ’Risk of bias’ table within the Characteristics of included
studies table; Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; and Summary of
findings 4.
Measures of treatment effect
1 Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive than odds ratios, and that odds
ratios tend to be interpreted as RR by clinicians (Boissel 1999;
Deeks 2000). The number needed to treat for an additional ben-
eficial outcome/number needed to treat for an additional harmful
outcome statistic with its CIs is intuitively attractive to clinicians
but is problematic both in its accurate calculation inmeta-analyses
and its interpretation (Hutton 2009). For binary data presented
in the Summary of findings for the main comparison, where pos-
sible, we calculated illustrative comparative risks.
2 Continuous data
For continuous outcomes, we estimatedMDbetween groups with
95% CI. We preferred not to calculate effect size measures (stan-
dardised mean difference). However, if scales of very considerable
similarity had been used, we presumed there was a small difference
in measurement, and we calculated effect size and transformed the
effect back to the units of one or more of the specific instruments.
Unit of analysis issues
1 Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data pose problems. Authors often fail to account for in-
traclass correlation in clustered studies, leading to a ’unit of anal-
ysis’ error (Divine 1992), whereby P values are spuriously low,
CIs unduly narrow, and statistical significance overestimated. This
causes type I errors (Bland 1997; Gulliford 1999).
If clustering had not been accounted for in primary studies, we
would have presented data in a table, with an asterisk symbol to
indicate the presence of a probable unit of analysis error. In subse-
quent versions of this review, wewill seek to contact first authors of
studies to obtain intraclass correlation coefficients (ICCs) for their
clustered data and to adjust for this by using accepted methods
(Gulliford 1999). If clustering was incorporated into the analysis
of primary studies, we would have presented these data as if from
a non-cluster randomised study, but adjusted for the clustering
effect.
We sought statistical advice and were advised that the binary data
as presented in a report should be divided by a ’design effect’. We
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calculated this using the mean number of participants per cluster
(m) and the ICC (design effect = 1 + (m - 1) × ICC) (Donner
2002). If the ICC was not reported, we would have assumed it to
be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into ac-
count ICCs and relevant data documented in the report, we would
have synthesised these with other studies using the generic inverse-
variance technique.
2 Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase,
the participants can differ systematically from their initial state
despite a washout phase. For the same reason, cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
had planned to use only the data of the first phase of cross-over
studies.
3 Studies with multiple treatment groups
Where a study involvedmore than two treatment arms, if relevant,
we presented the additional treatment arms in comparisons. If data
were binary, we simply added these and combined them within
the two-by-two table. If data were continuous, we combined data
following the formula in Section7.7.3.8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Where the
additional treatment arms were not relevant, we did not use these
data.
Dealing with missing data
1 Overall loss of credibility
At some degree of loss of follow-up data must lose credibility (Xia
2009). We chose that, for any outcome, should more than 50% of
the data be unaccounted for, we would not reproduce these data
or use them within analyses (except for the outcome ’leaving the
study early’). However, if more than 50% of those in one arm of
a study were lost, but the total loss was less than 50%, we would
have marked such data with an asterisk to indicate that such a
result may well be prone to bias.
2 Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we
presented data on a ’once-randomised-always-analyse’ basis (an
intention-to-treat analysis). We assumed all participants leaving
the study early to have the same rates of negative outcome as
participants who completed, except for the outcomes of death and
adverse effects. For these outcomes, we used the rate of participants
who stayed in the study - in that arm of the trial - for participants
who did not.We undertook a sensitivity analysis to test how prone
the primary outcomes were to change when data only from people
who completed the study to that point were compared to the
intention-to-treat analysis using the above assumptions.
3 Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who completed the study
to that point were reported, we used these data.
3.2 Standard deviations
If in future updates SDs are not reported, we will first try to obtain
the missing values from the authors. If these are not available,
where measures of variance for continuous data are missing, but
an exact standard error (SE) and CIs are available for group means,
and either P value or t value is available for differences in mean,
we can calculate them according to the rules described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). When only the SE is reported, SDs can be calculated by
the formula SD = SE × square root (n). Sections 7.7.3 and 16.1.3
of the Cochrane Handbook for Systematic Reviews of Interventions
present detailed formulae for estimating SDs from P values, t or
F values, CIs, ranges or other statistics (Higgins 2011). If these
formulae do not apply, we will calculate the SDs according to
a validated imputation method that is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information.
We nevertheless will examine the validity of the imputations in a
sensitivity analysis excluding imputed values.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results (Leucht 2007). Therefore, where LOCF data were used in
the trial, if less than 50% of the data were assumed, we presented
and used these data and indicated that they were the product of
LOCF assumptions.
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Assessment of heterogeneity
1 Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations that we had
not predicted would arise. If such situations or participant groups
arose, we would have fully discussed these.
2 Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods that we had not
predicted would arise. If such methodological outliers had been
present, we would have fully discussed these.
3 Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 method alongside the Chi2 P value. The I2 statistic provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
the I2 statistic depends on the magnitude and direction of effects
and the strength of evidence for heterogeneity (e.g. P value from
Chi2 test, or a CI for the I2 statistic). We interpreted an I2 statistic
estimate of 50% or greater accompanied by a statistically signifi-
cant Chi2 statistic as evidence of substantial levels of heterogeneity
(Higgins 2011). When we found substantial levels of heterogene-
ity in the primary outcome, we explored reasons for heterogeneity
(Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1 Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are de-
scribed in Section 10.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We tried to locate proto-
cols of included RCTs. If the protocol was available, we compared
outcomes in the protocol with those in the published report. If
the protocol was not available, we compared outcomes listed in
the methods section of the trial report with reported results.
2 Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We did not
use funnel plots for outcomes where there were 10 or fewer studies,
or where all studies were of similar size. In future updates of this
review, if funnel plots are possible, we will seek statistical advice
in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seemed to be true to us, and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. However, there is a disadvantage to the
random-effects model, in that it puts added weight on to small
studies, which often are the most biased ones. Depending on the
direction of effect, these studies can either inflate or deflate the
effect size. We chose the fixed-effect model for all analyses.
Subgroup analysis and investigation of heterogeneity
1 Subgroup analyses
1.1 Primary outcomes
We did not anticipate a need for any subgroup analysis.
1.2 Clinical state, stage or problem
We proposed to undertake this review as part of a family of similar
reviews that will provide an overview of the effects of droperidol for
people with psychosis induced aggression or agitation in general.
In addition, we aimed to report data on subgroups of people in
the same clinical state, stage and with similar problems.
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2 Investigation of heterogeneity
If inconsistency was high, we reported this. We first investigated
whether data had been entered correctly. Second, if data were cor-
rect, we visually inspected the graph and successively removed out-
lying studies to see if homogeneity was restored. For this review,
we decided that should this occur with data contributing to the
summary finding of nomore than around 10%of the total weight-
ing, we would present the data. If not, we would not pool the
data and we would discuss these issues. We know of no supporting
research for this 10% cutoff, but we used prediction intervals as
an alternative to this unsatisfactory state.
If in future updates of this reviewunanticipated clinical ormethod-
ological heterogeneity is obvious, we will simply state hypotheses
regarding these. We do not anticipate undertaking analyses relat-
ing to such situations.
Sensitivity analysis
1 Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in such away as to imply randomisation. For the primary
outcomes, we would have included these studies, and if there was
no substantive difference when the implied randomised studies
were added to those with better description of randomisation, then
we would have employed all data from these studies.
2 Assumptions for lost binary data
Where we had to make assumptions regarding people lost to fol-
low-up (see Dealing with missing data), we compared the findings
of the primary outcomes when we used our assumption(s) and
when we used data only from people who completed the study
to that point. If there was a substantial difference, we would have
reported results and discussed them but continued to employ our
assumption.
If we had needed to make assumptions regarding missing SDs
data (see Dealing with missing data), we would have compared the
findings of the primary outcomes whenwe used our assumption(s)
and whenwe used data only from people who completed the study
to that point. We would have undertaken a sensitivity analysis
testinghowprone resultswere to changewhen completer-only data
only were compared to imputed data using the above assumption.
If there was a substantial difference, wewould have reported results
and discussed them but continued to employ our assumption.
3 Risk of bias
For the primary outcome, we analysed the effects of excluding
trials that we judged to be at high risk of bias across one or more
of the domains of randomisation (implied as randomised with
no further details available) allocation concealment, blinding and
outcome reporting. If the exclusion of trials at high risk of bias
had substantially altered the direction of effect or the precision of
the effect estimates, then we would not have included data from
these trials in the analysis.
4 Imputed values
We had intended to undertake a sensitivity analysis to assess, if
necessary, the effects of including data from trials where we used
imputed values for ICC in calculating the design effect in cluster
randomised trials.
If we had noted substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not have pooled data from the excluded trials with the
other trials contributing to the outcome, but would have presented
them separately.
5 Fixed effect and random effects
We synthesised all data using a fixed-effect model, however we also
aimed to synthesise data for the primary outcome using a random-
effects model to evaluate whether this altered the significance of
the results. If the significance of results changed, we would have
noted this in the text.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
We included six studies in this review. In the update search, we
undertook for this review, we found 14 records that were poten-
tially relevant. We identified no duplicates. We screened these 14
records and removed two records. We assessed 12 full-text articles
for eligibility and excluded six from the review with reasons. Three
of these studies were already included in the previous version of
the review and we added three new studies. The PRISMA table
shows results of our search (Figure 2).
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Figure 2. 2015 study flow diagram.
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Included studies
1 Methods
All the included trials were randomised including one study that
employed block randomisation (Calver 2015). Five out of six in-
cluded trials were double-blind (Chan 2013; Cocchi 1971; Knott
2006; Resnick 1984; Van Leeuwen 1977), while Resnick 1984
gave no clear details of blinding. In an effort to minimise bias,
three of the included studies stated that the outcome assessor was
blind to group allocation (Calver 2015; Chan 2013; Knott 2006),
one study reported no detail of blinding the outcome assessor (Van
Leeuwen 1977).
2 Length of trials
The overall duration of the included trials varied in length from
immediate (within two hours), short term (more than two hours
to 24 hours) to long term (beyond 2 weeks) as listed in Table 5.
3 Participants
A total of 733 people participated in the six studies. Three of
the included studies included more than 100 participants (Calver
2015;Chan 2013;Knott 2006); the remaining studies included40
(Cocchi 1971), 27 (Resnick 1984), and 41 (Van Leeuwen 1977)
participants. Only three studies specified inclusion of both male
and female participants (Calver 2015; Cocchi 1971; Van Leeuwen
1977).
All trials included people with psychoses. Resnick 1984 did not
specify beyond stating that participants were admitted involun-
tarily to the emergency department of a psychiatric unit. Van
Leeuwen 1977 included people with schizophrenia, manic depres-
sion or in a ’confusional state’; however, 10 participants had no
specific diagnosis. Cocchi 1971 stated that all participants had
schizophrenia.
All studies included people with acutely disturbed/aggressive/
agitated behaviour secondary to psychotic illnesses such as
schizophrenia, schizoaffective disorder, mixed affective disorders,
the manic phase of bipolar disorder or a brief psychotic episode,
irrespective of age and sex. For the 2015 update, we widened the
criteria to include studies where themajority of people in the study
had some form of mental illness that was thought to be fuelling
their aggression/agitation. We included these studies even if their
data were ’contaminated’ by data relating to people who were ag-
gressive for reasons other than mental illness. Therefore, we in-
cluded Knott 2006 (60% of participants hadmental illness) in the
review. However, none of the studies employed diagnostic criteria;
it is unknown whether this influenced the validity of findings.
Five out of six trials referred to the current clinical state of
participants: agitation or aggression (Calver 2015; Chan 2013);
schizophrenic - acutely exacerbated (Cocchi 1971); marked agita-
tion requiring chemical restraint (Knott 2006); unspecified psy-
chosis (Resnick 1984); and a combination of schizophrenia, ma-
nia, confusional state and miscellaneous disorders (Van Leeuwen
1977).
4 Setting
Two trials took place in large metropolitan emergency depart-
ments (Chan 2013; Knott 2006), andCalver 2015 was in a psychi-
atric intensive care unit of a large tertiary specialist mental health
facility in Australia. One trial was conducted in an Emergency
Department and Psychiatric crisis unit, Oregon Health Sciences
University, Portland (Resnick 1984). The setting of Van Leeuwen
1977 was unclear and Cocchi 1971 stated the trial took place in a
hospital setting.
5 Interventions
Trial drug 5 mg IM 5 mg IV 10 mg IM 10 mg IV
Droperidol
√
(Resnick 1984)
√
(Knott 2006; Chan 2013)
√
(Calver 2015)
√
(Van Leeuwen 1977)
Haloperidol
√
(Resnick 1984) -
√
(Calver 2015) -
Olanzapine -
√
(Chan 2013) - -
Midazolam -
√
(Knott 2006) - -
Placebo -
√
(Chan 2013) -
√
(Van Leeuwen 1977)
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(Continued)
IM: intramuscular; IV: intravenous.
6 Outcomes
6.1 Overall
The outcomes for which we could obtain useable data were: tran-
quillisation or asleep, global state, service use, mental state and
Adverse effects.
6.2 Outcome scales
The scales used by trials that provided useable data are described
below.
6.1.1 Mental state
i. Scale for Quantification of Psychotic Symptom Severity, high =
poor) (Goodrich 1953)
A research rating scale for use by hospital psychiatrists to ex-
press quantitatively the severity of ’incapacitation’ due to psychotic
symptoms. A rating of from 1.0 to 2.0, extreme behaviour disor-
ganisation requiring vigilance by hospital staff; from 2.0 to 3.0,
severity requiring “security ward” care; from 3.0 to 3.7, severity
requiring open convalescent ward care; and from 3.8 to 4.0, not
requiring hospitalisation, or person ready for discharge.
ii. Glasgow Coma Scale (Teasdale 1974)
The Glasgow Coma Scale (GCS) is a scoring system used to de-
scribe the level of consciousness in a person following a traumatic
brain injury. The test is simple, reliable, correlates well with out-
come and is an objective way of recording the initial and subse-
quent level of consciousness in a person after a brain injury. It is
used by trained staff at the site of an injury (e.g. at a car crash
or sports injury), and in the emergency department and intensive
care units. Clinicians use this scale to rate the best eye opening
response, the best verbal response and the best motor response
apersonmakes. Generally, brain injury is classified as ’severe’ (GCS
3 to 8, cannot score lower than 3), ’moderate’ (GCS 9 to 12) and
mild (GCS 13 to 15).
iii. Brief Psychiatric Rating Scale (Overall 1962)
The BPRS is used to assess the severity of a range of psychiatric
symptoms, including psychotic symptoms. The original scale has
16 items, although a revised 18-item scale is commonly used. Each
item is defined on a 7-point scale varying from ’not present’ to
’extremely severe’, scoring from 0 to 6 or 1 to 7. Total scores
can range from 0 to 126, with high scores indicating more severe
symptoms.
6.3 Missing outcomes
No trial reported outcomes directly relevant to satisfaction with
treatment, acceptance of treatment, quality of life or economics.
Excluded studies
See Characteristics of excluded studies table for details of excluded
studies and Table 6 for details of randomised excluded studies
which are potentially relevant to other reviews.
We excluded 14 studies, four of which were not randomised.
Girard 1972 and Lilburn 1977 were case-control studies, and
Weiser 1973 was a case series. After emails fromDr Hooper it was
clear that his study also had to be excluded, as allocation to groups
had not been random, with participants being alternately allo-
cated to either the treatment or the control intervention (Hooper
1983). Most of the remaining trials were excluded because par-
ticipants were not clearly experiencing psychotic illnesses. Foster
1995 included female participants undergoing minor gynaeco-
logical surgery. Richards 1998 and Thomas 1992 both included
predominantly ’intoxicated’ people. Thomas 1992 also included
people experiencing trauma, an underlying medical condition or
who were undiagnosed, as did Rosen 1997. Both Richards 1998
and Rosen 1997 included some people with a ’psychiatric’ diag-
nosis but their studies had to be excluded because outcomes for
these participants, a small minority of the total, were not separately
analysed. Cocito 1970 included only people with psychosis, but
not necessarily with acute illnesses, while Isbister 2010, although
randomised, did not mention any underlying psychiatric illness.
Weiser 1975 would have been included, except for the addition of
five people to replace those who left the study early. It is not clear
to which group(s) those leaving early belonged, so the remaining
data were rendered of little value once data from the non-random
replacements had been incorporated.
Awaiting assessment
No studies are currently awaiting assessment.
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Ongoing studies
We are not aware of any ongoing studies.
Risk of bias in included studies
See also ’Risk of bias’ tables in the Characteristics of included
studies table and Figure 3.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All the included trials were randomised including one study
(Calver 2015) that employed block randomisation. Van Leeuwen
1977 specified that treatment was “randomly assigned” with par-
ticipants listed in chronological order and assigned individually
numbered vials. Therefore, it was unclear whether those randomis-
ing could have ascertained the order of prescribing. Resnick 1984
did not specify the explicit means of allocation, although he stated
that participants received treatment on a ’randomised basis’, and
that the codes identifying the packages of medication were “kept
in the pharmacy until the conclusion of the study”. Cocchi 1971
specified only that the study was randomised, with no details re-
garding the means of allocation.
Blinding
Five out of six included trials were double-blind (Chan 2013;
Cocchi 1971; Knott 2006; Resnick 1984; Van Leeuwen 1977).
To minimise bias, three of the included studies stated that the
outcome assessor was blinded to group allocation (Calver 2015;
Chan2013;Knott 2006).One study reportednodetail of blinding
the outcome assessor (Van Leeuwen 1977), while Resnick 1984
gave no clear details of blinding.
Incomplete outcome data
We rated only three studies at low risk bias with regard to attrition
bias, as all participants were continued to follow-up (Calver 2015;
Chan 2013; Resnick 1984), and only one study with high risk of
attrition bias as it did not include all randomised participants in
the final analysis (Knott 2006). We rated two studies as having
unclear risk of bias (Cocchi 1971; Van Leeuwen 1977).
Selective reporting
All studies reported data for all outcomes listed. We rated five
studies at low risk of bias and one study at unclear risk of reporting
bias (Knott 2006).
Other potential sources of bias
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We identified no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparisonDroperidol
versus placebo; Summary of findings 2 Droperidol versus
haloperidol; Summary of findings 3 Droperidol versus
midazolam; Summary of findings 4Droperidol versus olanzapine
There are four comparisons: droperidol compared with placebo,
droperidol compared with haloperidol, droperidol compared with
midazolam and droperidol comparedwith olanzapine. The studies
reported outcomes for intervals within the ’immediate’ time frame
as defined in Criteria for considering studies for this review. We
reported these immediate outcomes individually.
1 Comparison 1: Droperidol versus placebo
Two studies provided data for the comparison of droperidol versus
placebo (Chan 2013, N = 227; Van Leeuwen 1977, N = 41).
1.1 Tranquillisation or asleep: 1. tranquilised/asleep
(minutes)
One study provided data for tranquillisation or asleep (Chan
2013).
1.1.1 By five minutes
There was no clear difference between droperidol and placebo for
by five minutes (1 RCT, N = 227, RR 1.32, 95% CI 0.90 to 1.96;
Analysis 1.1).
1.1.2 By 10 minutes
By 10 minutes, there was evidence that droperidol was clearly
different in its effects compared with placebo (1 RCT, N = 227,
RR 1.36, 95% CI 1.08 to 1.71; Analysis 1.1).
1.1.3 By 30 minutes
By 30 minutes, we found evidence of a clear difference between
droperidol and placebo (1 RCT, N = 227, RR 1.18, 95% CI 1.05
to 1.31; Analysis 1.1).
1.1.4 By 60 minutes
By 60 minutes, we found evidence of a clear difference between
droperidol and placebo (1 RCT, N = 227, RR 1.09, 95% CI 1.00
to 1.18; Analysis 1.1).
1.2 Tranquillisation or asleep: 2. difficulty in achieving
tranquillisation/sleep
Chan 2013 provided data for difficulty in achieving tranquillisa-
tion/sleep. There was no clear difference between droperidol and
placebo (1 RCT, N = 227, RR 0.51, 95%CI 0.10 to 2.75; Analysis
1.2).
1.3 Tranquillisation or asleep: 3. time to
tranquillisation/sleep
Chan 2013 provided data for time to tranquillisation/sleep. We
found evidence of a clear difference between droperidol and
placebo in the mean time (in minutes) taken to become tranquil
or asleep (1 RCT, N = 227, MD -46.50, 95% CI -86.83 to -6.17;
Analysis 1.3).
1.4 Global state: use of additional medication
Two studies provided data on use of additional medication (Chan
2013; Van Leeuwen 1977).
1.4.1 “To reach initial adequate sedation”
Chan 2013 provided data for numbers needing additional med-
ication to reach initial adequate sedation. We found evidence
that droperidol was clearly different in its effects compared with
placebo (1 RCT, N = 227, RR 0.50, 95%CI 0.28 to 0.89; Analysis
1.4).
1.4.2 By three minutes (haloperidol)
Van Leeuwen 1977 provided data for numbers needing additional
haloperidol by three minutes. We found evidence of a clear differ-
ence between droperidol and placebo for use of additional medi-
cation (1 RCT, N = 41, RR 0.37, 95% CI 0.18 to 0.72; Analysis
1.4).
1.4.3 By 30 minutes (any psychotropic drug)
Van Leeuwen 1977 provided data for numbers needing any addi-
tional psychotropic drug by 30 minutes. We found no evidence
of a clear difference between droperidol and placebo (1 RCT, N =
41, RR 0.46, 95% CI 0.17 to 1.24; Analysis 1.4).
1.4.4 By 60 minutes (midazolam, droperidol, olanzapine,
haloperidol)
Chan 2013 provided data for use of additional medication. By
60 minutes, there was evidence of a clear difference favouring
droperidol (1 RCT, N = 227, RR 0.64, 95% CI 0.42 to 0.96;
Analysis 1.4).
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1.4.5 From 60 minutes after initial adequate sedation until
emergency department discharge (various psychotropic
drugs)
We found evidence of a clear difference for use of additional med-
ication favouring droperidol (1 RCT, N = 227, RR 0.55, 95% CI
0.36 to 0.85; Analysis 1.4).
1.5 Adverse effects
Two studies provided adverse effect data (Chan 2013; Van
Leeuwen 1977).
1.5.1 Cardiovascular - arrhythmia
Chan 2013 provided data for arrhythmia. There was no clear dif-
ference between droperidol and placebo (1 RCT, N = 227, RR
0.34, 95% CI 0.01 to 8.31; Analysis 1.5).
1.5.2 Cardiovascular - hypotension
Chan 2013 provided data for hypotension. We found no evidence
of a clear difference between droperidol and placebo (1 RCT, N =
227, RR 0.68, 95% CI 0.20 to 2.36; Analysis 1.5).
1.5.3 Central nervous system - oversedation (decreased
Glasgow Coma Score of 6)
Chan 2013 provided data for oversedation. We found no evidence
of a clear difference between droperidol and placebo (1 RCT, N =
227, RR 0.34, 95% CI 0.01 to 8.31; Analysis 1.5).
1.5.4 Respiratory - airway obstruction
Chan 2013 provided data for airway obstruction. There was no-
clear difference between droperidol and placebo (1 RCT, N = 227,
RR 0.62, 95% CI 0.15 to 2.52; Analysis 1.5).
1.5.5 Respiratory - oxygen desaturation
Chan 2013 provided data for oxygen desaturation. We found no
evidence of a clear difference between droperidol and placebo (1
RCT, N = 227, RR 1.03, 95% CI 0.42 to 2.49; Analysis 1.5).
1.5.6 Unspecified - by three minutes
One trial provided data for unspecified Adverse effects by three
minutes (Van Leeuwen 1977, N = 41). There were no events in
either the droperidol or placebo group (Analysis 1.5).
1.6 Service use: person able to be discharged home
Chan 2013 provided data for discharge. There was no clear dif-
ference between droperidol and placebo (N = 227, RR 1.16, 95%
CI 0.90 to 1.48; Analysis 1.6).
1.7 Service use: emergency department length of stay
Chan2013 (N=227) provideddata for length of stay in emergency
department. Data were skewed and can be viewed in Analysis 1.7).
There was no suggestion of a difference between droperidol and
placebo (median stay was around 10 hours for both groups).
2 Comparison 2: Droperidol versus haloperidol
Three studies provided data for the comparison of droperidol ver-
sus haloperidol (Calver 2015, N = 228; Cocchi 1971, N = 40;
Resnick 1984, N = 27).
2.1 Tranquillisation or asleep: 1. tranquillised/sleep within
120 minutes
Calver 2015 provided useable data for tranquillised/sleep within
120 minutes. We found no evidence of a clear difference between
droperidol and haloperidol(1 RCT, N = 228, RR 1.01, 95% CI
0.93 to 1.09).
2.2 Tranquillisation or asleep: 2. time to
tranquillisation/sleep
Calver 2015 provided data for time to tranquillisation/sleep, we
have presented them in Analysis 2.2. There was no suggestion of
clear difference between droperidol and haloperidol (median time
was around 25 minutes for both groups).
2.3 Global state: use of additional medication
2.3.1 Midazolam administered initially
Calver 2015 provideddata that showedno clear difference between
droperidol and haloperidol for use of additional medication (1
RCT, N = 228, RR 3.26, 95% CI 0.69 to 15.37; Analysis 2.3).
2.3.2 By 30 minutes
Resnick 1984 provided data for use of additional medication by
30 minutes. We found no clear difference between droperidol and
haloperidol (1 RCT, N = 27, RR 0.45, 95% CI 0.20 to 1.01;
Analysis 2.3).
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2.3.3 By 60 minutes
Two trials provided data for use of additional medication by 60
minutes (Calver 2015; Resnick 1984). There was evidence of a
clear effect, favouring droperidol for this outcome. (2 RCTs, N =
255, RR 0.37, 95% CI 0.16 to 0.9; Analysis 2.3).
2.3.4 By 90 minute
Resnick 1984 provided data for use of additional medication by
90 minutes. There was no evidence of a clear difference between
droperidol and haloperidol(1 RCT, N = 27, RR 0.47, 95% CI
0.02 to 10.63; Analysis 2.3).
2.4 Global state: no overall improvement - by 30 days
Cocchi 1971 provided data for overall improvement. There was
no clear difference between droperidol and haloperidol (1 RCT,
N = 40, RR 0.67, 95% CI 0.29 to 1.52; Analysis 2.4).
2.5 Adverse effects
One study provided adverse effect data (Calver 2015, N = 228).
2.5.1 Cardiovascular - hypotension
There was no clear difference between droperidol and haloperidol
for hypotension (RR 2.80, 95% CI 0.30 to 26.49; Analysis 2.5).
2.5.2 Cardiovascular - hypotension/desaturation
We found no evidence of a clear difference between the two treat-
ments for hypotension/desaturation (RR 2.80, 95% CI 0.12 to
67.98; Analysis 2.5).
2.5.3 Central nervous system - extrapyramidal adverse effects
There was no clear difference in extrapyramidal adverse effects
between droperidol and haloperidol (RR 2.80, 95% CI 0.12 to
67.98; Analysis 2.5).
2.5.4 Central nervous system - oversedation
There was no clear difference between droperidol and haloperidol
for oversedation (RR 2.80, 95% CI 0.12 to 67.98; Analysis 2.5).
2.5.5 Staff injuries
There was no evidence of a clear difference in staff injuries between
droperidol and haloperidol (RR 0.56, 95% CI 0.14 to 2.29;
Analysis 2.5).
2.6 Mental state: mean score by 13 days (Scale for
Quantification of Psychotic Symptom Severity, high = poor)
Cocchi 1971, N = 40 provided mental state data and we found no
evidence of a clear difference between droperidol and haloperidol
(MD 0.11, 95% CI -0.07 to 0.29; Analysis 2.6).
3 Comparison 3: Droperidol versus midazolam
One study provided data for the comparison of droperidol versus
midazolam (Knott 2006, N = 153).
3.1 Tranquillisation or asleep: 1. tranquillised/asleep
We identified one study relevant to this outcome and categorised
data into two subsets: by 5 minutes and by 10 minutes.
3.2.1 By five minutes
We found evidence of a clear difference between droperidol and
midazolam by five minutes (RR 0.37, 95% CI 0.21 to 0.64;
Analysis 3.1).
3.2.2 By 10 minutes
There was no clear difference between droperidol and midazolam
by 10 minutes (RR 0.96, 95% CI 0.72 to 1.28; Analysis 3.1).
3.2 Tranquillisation or asleep: 2. time to
tranquillisation/sleep
There was no suggestion of a clear difference between droperidol
and midazolam (median time was around 10 minutes for both
groups; Analysis 3.2).
3.3 Global state: use of additional medication
We foundone study reportingdata onuse of additionalmedication
and categorised data into one subset involving 153 participants
(Knott 2006).
3.3.1 By 60 minutes
There was no clear difference between droperidol and midazolam
by 60 minutes (RR 0.54, 95% CI 0.24 to 1.20; Analysis 3.3).
3.4 Adverse effects
One study provided adverse effect data (Knott 2006, N = 153).
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3.4.1 Cardiovascular - arrhythmia (bradycardia)
There was no evidence of a clear difference between droperidol
and midazolam for arrhythmia (RR 2.81, 95% CI 0.12 to 67.98;
Analysis 3.4).
3.4.2 Cardiovascular - hypotension
There was no clear difference between droperidol and midazolam
for hypotension (RR 0.70, 95% CI 0.16 to 3.03; Analysis 3.4).
3.4.3 Central nervous system - dystonic reaction
There was no evidence of a clear difference between droperidol
and midazolam for dystonic reaction (RR 6.56, 95% CI 0.34 to
124.93; Analysis 3.4).
3.4.4 Central nervous system - seizure
Therewere no seizures in either the droperidol ormidazolamgroup
(Analysis 3.4).
3.4.5 Gastric - aspiration
There were no aspirations in either the droperidol or midazolam
group (Analysis 3.4).
3.4.6 Gastric - vomiting
There were no vomiting episodes in either the droperidol or mi-
dazolam group (Analysis 3.4).
3.4.7 Respiratory - airway management
There was no evidence of a clear difference between droperidol
and midazolam (RR 0.13, 95% CI 0.01 to 2.55; Analysis 3.4).
3.4.8 Respiratory - assistance with ventilation
There was no need for assistance with ventilation with either
droperidol or midazolam (Analysis 3.4).
3.4.9 Respiratory - hypoxia
There was no clear difference between droperidol and midazolam
for hypoxia (RR 0.70, 95% CI 0.16 to 3.03; Analysis 3.4)
4 Comparison 4: Droperidol versus olanzapine
One study provided data for the comparison of droperidol versus
olanzapine (Chan 2013). In this comparison, there were seven
outcomes.
4.3 Tranquillisation or asleep: 3. tranquillised/asleep
We divided the data into four subsets, with a total of 884 people.
There was no clear difference between droperidol and olanzapine
(RR 1.00, 95% CI 0.93 to 1.07).
4.3.1 At five minutes
There was no clear difference between droperidol and olanzapine
at five minutes (RR 1.00, 95% CI 0.70 to 1.42; Analysis 4.1).
4.3.2 At 10 minutes
There was no evidence of a clear difference between droperidol
and olanzapine at 10 minutes (RR 0.97, 95% CI 0.81 to 1.17;
Analysis 4.1).
4.3.3 At 30 minutes
There was no clear difference between droperidol and olanzapine
at 30 minutes (RR 1.02, 95% CI 0.94 to 1.11; Analysis 4.1).
4.3.4 At 60 minutes
There was no clear difference between droperidol and olanzapine
at 60 minutes (RR 0.99, 95% CI 0.93 to 1.05; Analysis 4.1).
4.2 Tranquillisation or asleep: 2. difficulty in achieving
tranquillisation/sleep
We found no evidence of a clear difference between droperidol and
olanzapine for difficulty in achieving tranquillisation/sleep (RR
0.65, 95% CI 0.11 to 3.81; Analysis 4.2).
4.3 Tranquillisation or asleep: 3. time to
tranquillisation/sleep
There was no clear difference between droperidol and olanzapine
for time to tranquillisation/sleep (in minutes) (1 RCT, N = 221,
MD 7.3 95% CI -11.74 to 26.34; Analysis 4.3).
4.4 Global state: use of additional medication
We identified one study reporting use of additional medication
and categorised data into three subsets (Chan 2013, N = 221).
4.4.1 “To reach initial adequate sedation”
There was no clear difference between droperidol and olanzapine
for use of additional medication “to reach initial adequate seda-
tion” (RR 0.68, 95% CI 0.36 to 1.28; Analysis 4.4).
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4.4.2 By 60 minutes (midazolam, droperidol, olanzapine,
haloperidol)
We found no evidence of a clear difference between droperidol
and olanzapine for use of additional medication by 60 minutes
(RR 1.01, 95% CI 0.63 to 1.64; Analysis 4.4).
4.4.3 From 60 minutes after initial adequate sedation until
emergency department discharge (various psychotropic
drugs)
We found evidence of a clear difference, favouring droperidol for
use of additionalmedication from60minutes after initial adequate
sedation until emergency department discharge (RR 0.56, 95%
CI 0.36 to 0.87; Analysis 4.4).
4.5 Adverse effects
One study provided adverse effect data (Chan 2013, N = 221).
We divided the data into five subsets.
4.5.1 Cardiovascular - arrhythmia
There was no clear difference between droperidol and olanzapine
for arrhythmia (RR 0.32, 95% CI 0.01 to 7.88; Analysis 4.5).
4.5.2 Cardiovascular - hypotension
There was no clear difference between droperidol and olanzapine
for hypotension (RR 1.30, 95% CI 0.30 to 5.66; Analysis 4.5).
4.5.3 Central nervous system - decreased Glasgow Coma
Score (score of 6)
There were no reports of decreased GCS (score of 6) in either the
droperidol or olanzapine group (Analysis 4.5).
4.5.4 Respiratory - airway obstruction
We found no evidence of a clear difference between droperidol
and olanzapine (RR 0.97, 95% CI 0.20 to 4.72; Analysis 4.5).
4.5.5 Respiratory - oxygen desaturation
We found no evidence of a clear difference between droperidol
and olanzapine (RR 1.75, 95% CI 0.61 to 5.06; Analysis 4.5).
4.6 Service use: 1. person able to be discharged home
One study provided data for discharge (Chan 2013, N = 221).
There are no subsets in this outcome. We found no evidence of
a clear difference between droperidol and olanzapine (RR 1.06,
95% CI 0.83 to 1.34; Analysis 4.6).
4.7 Service use: 2. emergency department length of stay
One study provided data for length of stay in emergency depart-
ment (N = 221). There was no suggestion of clear difference be-
tween droperidol and olanzapine (median stay was around 11
hours for both groups; Analysis 4.7).
5 Missing outcomes
We found no data for satisfaction with treatment, acceptance of
treamtent, quality of life or economic outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Droperidol versus haloperidol
Patient or population: acute psychosis
Setting: inpat ient
Intervention: droperidol
Comparison: haloperidol
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with haloperidol Risk with droperidol
Tranquillisa-
t ion or asleep: tranquil-
lised/ sleep - by around
30 minutes
Moderate RR 1.01
(0.93 to 1.09)
228
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion920 per 1000 929 per 1000
(856 to 1000)
Global state: use of ad-
dit ional medicat ion - by
60 minutes af ter init ial
adequate sedat ion unt il
ED discharge (various
psychotropic drugs)
Moderate RR 0.37
(0.16 to 0.90)
255
(2 RCTs)
⊕⊕⊕⊕
High 1,2
’Moderate’ control risk
approximately that of
trial populat ion
160 per 1000 59 per 1000
(26 to 144)
Adverse ef fects - car-
diovascular - hypoten-
sion
Moderate RR 2.80
(0.30 to 26.49)
228
(1 RCT)
⊕⊕⊕©
Moderate 1,3
’Moderate’ control risk
approximately that of
trial populat ion10 per 1000 28 per 1000
(3 to 265)
Adverse ef fects - car-
diovascular - hypoten-
sion/ desaturat ion
Study populat ion RR 2.80 (0.12 to 67.98) 228
(1 RCT)
⊕⊕©©
Low 1,3,4
’Moderate’ control risk
approximately that of
trial populat ion0 per 1000 0 per 1000
(0 to 0)
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Service use: person
able to be discharged
home
Study populat ion Not pooled (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
Mental state: mean
score by 13 days
(Scale for Quantif ica-
t ion of Psychot ic Symp-
tom Severity, high =
poor)
The mean mental state:
mean score by 13 days
(Scale for Quantif ica-
t ion of Psychot ic Symp-
tom Severity, high =
poor) was 0
The mean mental state:
mean score by 13 days
(Scale for Quantif ica-
t ion of Psychot ic Symp-
tom Severity, high =
poor) in the intervent ion
group was 0.11 unde-
f ined more (0.07 fewer
to 0.29 more)
MD 0.11
CI -0.07 to 0.29
40
(1 RCT)
⊕⊕©©
Low 1,3,4
’Moderate’ control risk
approximately that of
trial populat ion
Economic: direct costs Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ED: emergency department; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias: rated ’not serious’ (no downgrade) - clear report ing of good methods.
2 Indirectness: rated ’not serious’ (no downgrade) - but proxy outcome for ’Another episode of aggression by 24 hours’.
3 Imprecision: rated ’serious’ (downgraded by 1) - few events, wide conf idence intervals.
4 Indirectness: rated ’serious’ (downgraded by 1) - hypotension/ desaturat ion proxy measure - not ’death’.
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Droperidol versus midazolam
Patient or population: acute psychosis
Setting: inpat ient
Intervention: droperidol
Comparison: midazolam
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with midazolam Risk with droperidol
Tranquillisat ion
or asleep: tranquillised/
asleep - by 30 minutes
(at 10 minutes)
Moderate RR 0.96
(0.72 to 1.28)
153
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion550 per 1000 528 per 1000
(396 to 704)
Global state: use of ad-
dit ional medicat ion - by
60 minutes af ter init ial
adequate sedat ion unt il
ED discharge (various
psychotropic drugs)
Moderate RR 0.54 (0.24 to 1.20) 153
(1 RCT)
⊕⊕⊕©
Moderate 1,2
’Moderate’ control risk
approximately that of
trial populat ion
190 per 1000 101 per 1000
(42 to 224)
Adverse ef fects - respi-
ratory - airway obstruc-
t ion
Moderate RR 0.13
(0.01 to 2.55)
153
(1 RCT)
⊕⊕©©
Low 1,2,3
’Moderate’ control risk
approximately that of
trial populat ion40 per 1000 5 per 1000
(0 to 102)
Adverse ef fects - respi-
ratory - hypoxia
Moderate RR 0.70
(0.16 to 3.03)
153
(1 RCT)
⊕⊕⊕©
Moderate 1,2
’Moderate’ control risk
approximately that of
trial populat ion50 per 1000 35 per 1000
(8 to 143)
Service use: person
able to be discharged
home
Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
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Not pooled Not pooled
Mental state - improve-
ment
Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
Economic: direct costs Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ED: emergency department; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias: rated ’not serious’ (no downgrade) - clear report ing of good methods.
2 Imprecision: rated ’serious’ (downgraded by 1) - few events, wide conf idence intervals.
3 Indirectness: rated ’serious’ (downgraded by 1) - respiratory obstruct ion proxy measure - not ’death’.
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Droperidol versus olanzapine
Patient or population: acute psychosis
Setting: inpat ient
Intervention: droperidol
Comparison: olanzapine
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with olanzapine Risk with droperidol
Tranquillisat ion
or asleep: tranquillised/
asleep - by around 30
minutes
Moderate RR 1.02
(0.94 to 1.11)
221
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion900 per 1000 918 per 1000
(846 to 999)
Global state: use of ad-
dit ional medicat ion - by
60 minutes af ter init ial
adequate sedat ion unt il
ED discharge (various
psychotropic drugs)
Moderate RR 0.56
(0.36 to 0.87)
221
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion
370 per 1000 207 per 1000
(133 to 322)
Adverse ef fects - car-
diovascular - arrhyth-
m ia
Moderate RR 0.32
(0.01 to 7.88)
221
(1 RCT)
⊕⊕⊕©
Moderate 1,2
’Moderate’ control risk
approximately that of
trial populat ion10 per 1000 3 per 1000
(0 to 79)
Adverse ef fects - respi-
ratory - airway obstruc-
t ion
Moderate RR 0.97
(0.20 to 4.72)
221
(1 RCT)
⊕⊕©©
Low 2,3
’Moderate’ control risk
approximately that of
trial populat ion30 per 1000 29 per 1000
(6 to 142)
Service use: person
able to be discharged
home
Moderate RR 1.06
(0.83 to 1.34)
221
(1 RCT)
⊕⊕⊕⊕
High 1
’Moderate’ control risk
approximately that of
trial populat ion
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530 per 1000 562 per 1000
(440 to 710)
Mental state - improve-
ment
Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
Economic: direct costs Study populat ion Not est imable (0 studies) - No trial reported this
important outcome.
Not pooled Not pooled
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ED: emergency department; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias: rated ’not serious’ (no downgrade) - clear report ing of good methods.
2 Imprecision: rated ’serious’ (downgraded by 1) - few events, wide conf idence intervals.
3 Indirectness: rated ’serious’ (downgraded by 1) - respiratory obstruct ion proxy measure - not ’death’.
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D I S C U S S I O N
Summary of main results
1 Comparison 1: droperidol versus placebo
1.1 Tranquillisation or asleep: tranquillised/sleep/global
state/service use
By 30 minutes, data that we categorise as being of ’high qual-
ity’ derived from a single trial of over 200 people suggested that
droperidol was more acutely tranquillising than placebo (Analysis
1.1). This would fit with clinical experience. This finding also fits
with the clear demonstration within the same study of reduced risk
of needing additional medication (Analysis 1.4). For the outcome
of being ready for discharge, there was no clear difference between
groups (RR 1.16, 95% CI 0.9 to 1.48).
1.2 Adverse effects
The one relevant trial (N = 227) found no evidence that droperi-
dol caused more cardiovascular arrhythmia and respiratory airway
obstruction than placebo. Droperidol has become less accessible
because it has been reported that people who receive droperidol are
at higher risk of QT prolongation (Wooltorton 2002). We found
no evidence for concern in these short trials for people with acute
aggressive behaviour.
1.3 Missing outcomes
It seems worth noting that the one study we found did not report
any key outcomes for mental state and none for costs. The global
state reported were very useful and, perhaps, trialists considered
them to be adequate for the purposes of this question. However,
some type of economic consideration of the outcomes is always
important and omission of this from a trial conducted in 2012 to
2013 leaves managers and policy makers less informed than they
could have been.
2 Comparison 2: droperidol versus haloperidol
2.1 Tranquillisation or asleep: tranquillised/sleep/global
state/mental state
By 30 minutes, data that we categorised as being of ’high quality’
from a single trial of over 200 people suggested that droperidol
was more acutely tranquillising than haloperidol (Analysis 2.1).
This finding also fits with the clear demonstration within the same
and one other study of reduced risk of needing additional medi-
cation (Analysis 2.3). For mental state, there was no evidence of
clear difference between the efficacy of droperidol and haloperi-
dol (Scale for Quantification of Psychotic Symptom Severity:MD
0.11, 95% CI -0.07 to 0.29) in terms of a reduced mean score by
13 days (Analysis 2.6). This is probably no surprise as key effects
of importance in this acutely aggressive situation are measured in
hours and by nearly two weeks it would seem unlikely that there
should be a discernible difference.
2.2 Adverse effects
The one relevant trial (N = 228) found no evidence that droperi-
dol caused more cardiovascular hypotension and cardiovascular
hypotension/desaturation than haloperidol (Analysis 2.5). There
was no suggestion that use of droperidol was unsafe.
2.3 Missing outcomes
The one included trial did not report outcomes of service use and
costs. Acknowledging their importance, global and mental state
were adequately reported. However, economic consideration and
service use were omitted from the study which leaves managers
and policy makers less informed regarding the cost effectiveness
of droperidol over haloperidol.
3 Comparison 3: droperidol versus midazolam
3.1 Tranquillisation or asleep: tranquillised/asleep/global
state
By 30 minutes, data that we categorised as being of ’high quality’
derived from a single trial of more than 200 people suggested that
droperidol was less acutely tranquillising than midazolam in the
first fewminutes (Analysis 3.1). This would fit with what is known
aboutmidazolam fromother studies. This finding does not fit with
the suggestion within the same study of reduced risk of needing
additional medication (Analysis 3.3).
3.2 Adverse effects
The one relevant trial (N = 153) reported no statistically signifi-
cant differences between droperidol and midazolam - but use of
midazolam did result in three people (out of around 70) needing
some type of ’airway management’ with no such events in the
droperidol group. Respiratory depression remains a known con-
cern with midazolam (TREC 2003). It is entirely reversible with
the use of flumazenil but even these small trials involving midazo-
lam suggested that use of this effective compound should continue
to be in units skilled in recognition of respiratory problems and
their management (Analysis 3.4).
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3.3 Missing outcomes
The one relevant study did not report service use, mental state
and economic costs. Omitting mental state from a study leaves
the clinicians less informed of the relative efficacy of droperidol
compared to midazolam. Likewise, not reporting important out-
come of costs leaves managers and policy makers less informed
regarding the cost effectiveness of droperidol over haloperidol.
4 Comparison 4: droperidol versus olanzapine
4.1 Tranquillisation or asleep: tranquillised/asleep/global
state/service use
By any time point, we found no clear differences between the older
drug (droperidol) and olanzapine (Analysis 4.1). There also was
a suggestion that participants allocated to droperidol needed less
additional medication than people given the olanzapine (Analysis
4.4). This would fit with clinical experience and other studies of
a similar nature (Raveendran 2007).
4.2 Adverse effects
The one relevant trial (N = 221) found no evidence that droperi-
dol caused more cardiovascular arrhythmia and respiratory airway
obstruction than olanzapine. The concern regarding droperidol
and QT prolongation is not obviously supported by the data we
found. We found no evidence for concern in this short trial for
people with acute aggressive behaviour.
4.3 Missing outcomes
We found no economic data. However, droperidol should be
cheaper than the olanzapine preparation which may in itself in-
crease the risk of further administration of medications. It would
seem that droperidol could be both as or more effective and more
cost effective.
Overall completeness and applicability of
evidence
1 Completeness
Evidence was certainly relevant, but overall data were too sparse
to extensively address the objectives of this review. The search
strategy identified six trials involving 733 participants compar-
ing droperidol to placebo, non-standard medication and standard
medication. The included studies addressed most of the outcomes
being investigated for this review. However, there still were a few
outcomes which were not catered for by the trials. These missing
outcomes, such as costs, are of prime importance when estimating
the cost effectiveness of droperidol when compared with placebo,
other ’standard’ treatments or ’non-standard’ treatments.
2 Applicability
The included trials were set in psychiatric hospitals, emergency
departments and psychiatric crisis units. All trials included people
with psychoses. Resnick 1984 did not specify beyond stating that
participants were admitted involuntarily to the emergency depart-
ment of a psychiatric unit. Van Leeuwen 1977 included people
with schizophrenia, manic depression or in a ’confusional state’;
however, 10 participants had no specific diagnosis. Cocchi 1971
stated that all participants had schizophrenia. These inclusion cri-
teria should make any findings applicable to the acute manage-
ment of disturbed people thought to experience serious mental
illnesses. It is noteworthy that along with inclusion of need for re-
peat injection in the included studies, outcomes such as further ag-
gressive episodes, tranquillisation, sedation and mental state were
also included. However, it is desirable to include outcomes such as
quality of life, carer satisfaction, economic costs and loss to follow-
up.
Quality of the evidence
See also Risk of bias in included studies and Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3; and Summary of findings 4.
Overall the quality of the six include trials was moderate to high
based on GRADE. One of the fundamental prerequisites of a ran-
domised trial methodology is random sequence allocation which
all trials employed. Calver 2015 used block randomisation. Van
Leeuwen 1977 specified that treatment was “randomly assigned”
with participants listed in chronological order and assigned indi-
vidually numbered vials. Therefore, it is unclear whether the peo-
ple randomising participants could have ascertained the order of
prescribing. Resnick 1984 did not specify the explicit means of al-
location, although they stated that participants received treatment
on a “randomised basis”, and that the codes identifying the pack-
ages of medication were “kept in the pharmacy until the conclu-
sion of the study”. Cocchi 1971 specified only that the study was
randomised, with no details regarding the means of allocation. In
effort to minimise bias, most of the included trials were double-
blind. All studies reported data for all outcomes listed and were
therefore rated at low risk of bias with the exception of one study
(Knott 2006), which we rated as having unclear risk of reporting
bias. Therefore, we considered the quality of evidence high.
Potential biases in the review process
The search criteria on the Cochrane Schizophrenia Group Trials
Register (December 2015) are sufficiently robust to detect relevant
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studies. However, it is possible that we have failed to identify small
studies but we think it unlikely that we would have missed large
trials. Studies published in languages other thanEnglish, and those
with equivocal results, are often difficult to find (Egger 1997).
Our search was biased by use of English phrases. However, given
that the Cochrane Schizophrenia Group’s Register covers many
languages but is indexed in English we feel that this would not
have missed many studies within the register. For example, the
search uncovered two studies for which the title was only available
in Chinese characters. A Chinese-speaking colleague (Jun Xia)
checked these for relevance and neither were relevant to this review.
Furthermore, we were not blinded to the names of the authors,
institutions or journal of publication which may have introduced
some type of bias in the review process.
Agreements and disagreements with other
studies or reviews
A previous version of this review did not identify many studies
that met the inclusion criteria (Cure 2004).However, this updated
version of the review found three more relevant studies. At this
point, we are unaware of any other similar reviews or studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1 For people with psychotic illness
Acute psychotic illness, especially with agitated, aggressive or vi-
olent behaviours, may require rapid tranquillisation or sedation.
Droperidol, a butyrophenone neuroleptic that is no longer com-
mercially promoted or manufactured, remains a viable option for
this purpose based on more evidence from randomised controlled
trials in this 2016 update.
2 For clinicians
Intramuscular droperidol was once a popular choice for the acute
management of very psychotic aggressive and agitated people. The
first version of this review thought that evidence relating to use of
droperidol was of historical interest only (Cure 2004). This seems
to be untrue. Droperidol is still used. There remains compelling
evidence that droperidol has a place in short-termmanagement of
psychotic aggressive people. The evidence presented in this review
allows conclusions to be drawn about its comparative efficacy to
haloperidol, midazolam and olanzapine that concur with the im-
pressions of the effectiveness of these other compounds from other
sources. Clinicians could help evaluate these different approaches
by supporting clinically relevant randomised controlled trials. We
found no evidence of reasons for any more concern over cardiac
problems than with other approaches, and less for respiratory dif-
ficulties than midazolam.
3 For managers/policy makers
Currently it seems that people in Australia, Belgium, Brazil, Czech
Republic, Denmark, Finland, Greece, India, Italy, Netherlands,
New Zealand, South Africa, Spain, Sweden, Thailand, and the
USA have droperidol as one option for treatment of aggression
thought due to psychosis. Much evidence for other compounds or
approaches is no stronger than for this old drug.
Implications for research
1 General
As with all similar studies, public registration of a study before
randomisation commences would ensure that participants could
be confident that people would know that the study had at least
taken place. Better reporting of data would have allowed us to
determine the effects of this compound in emergency situations.
Newer trials tended to comply with CONSORTmaking it much
easier to understand themethods of the studies.We hope that trials
in the next version of this reviewwill go that one last and important
step and allow full access to all data (AllTrials; OpenTrials).
2 Specific
2.1 Reviews
Several of the excluded studies in this review would be relevant for
inclusion in related Cochrane reviews (Table 6).
2.2 Trials
This review highlights the urgent need for more good quality con-
trolled trials of other compounds for management of acute psy-
chosis that address outcomes of major importance such as quality
of life, economic costs and satisfaction of carers. We realise that
design of such studies takes time and a great deal of thought and
commitment. However, we have given this area some thought and
suggest the broad outline of a trial in Table 7.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Calver 2015
Methods Allocation: randomised.
Blinding: ’masked study’.
Duration: 120 minutes.
Settings: psychiatric intensive care unit of a large tertiary specialist mental health facility,
Australia
Participants Diagnosis: people with agitation or aggression admitted involuntarily to psychiatric
intensive care unit from the psychiatric emergency care centre
N = 228.
Age: ≥ 18 years.
Sex: men and women.
History: adults (> 18 years of age) with acute behavioural disturbance requiring parenteral
medication for sedation and in whom verbal de-escalation or oral medication (or both)
had failed
Excluded: people < 18 years old and willing to take oral medication for sedation without
physical restraint or seclusion
Interventions 1. Droperidol 10 mg IM. N = 118.
2. Haloperidol 10 mg IM. N = 110.
Outcomes Global state: time to sedation, failed sedation, use of additional sedation, successful
sedation
Adverse drug effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Block randomisation was used”.
Response: randomisation probably done.
Allocation concealment (selection bias) Low risk Quote: “Microsoft Excel was used to ran-
domly create blocks of four (ABAB, AABB,
etc.) or six (ABABAB, AAABBB, etc.). The
use of different block sizesmeant that it was
impossible to predict the next treatment”
Response: allocation concealment done.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The list of study codes with alloca-
tions was generated by a research assistant
and supplied to theCalvaryMater Newcas-
tle pharmacy, so that the investigators and
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Calver 2015 (Continued)
treating staff remained unaware of the allo-
cations”
Response: both participants and personnel
were blind to the allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The pharmacy re labelled the vials
of haloperidol or droperidol with study
numbers based on the list of allocations”
Response: blinding of outcome assessment
done.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There were 584 sedation episodes
during the 23-month study period and of
these 356 were not included in the analy-
sis because the treating clinician elected to
give labelled parenteral sedation... an initial
SAT score was recorded which was similar
to those of the study participants”
Response: participants initially recruited
were included in the final analysis
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk
Chan 2013
Methods Allocation: randomised.
Design: multicentre, randomised, double-blind, placebo-controlled, double-dummy,
clinical trial
Duration: initially at 5 minutes followed by at 10, 30 and 60 minutes
Settings: trial undertaken in 3 large metropolitan EDs.
Participants Diagnosis: people with agitation or aggression.
N = 227.
Age: 18 to 65 years.
Sex: not specified.
History: highly agitated people aged 18 to 65 years, requiring parenteral drug sedation
for acute agitation, as determined by a registrar (senior resident) or consultant emergency
physician
Excluded: people with known hypersensitivity or contraindication to midazolam,
droperidol or olanzapine; obvious reversible cause for agitation (e.g. hypotension, hy-
poxia, hypoglycaemia); knownpregnancy; acute alcohol withdrawal; received (within the
previous 12 hours) oral or parenteral sedative drug(s) either as usual or out-of-hospital
acute agitation treatment
Interventions 1. Droperidol 5 mg IV + placebo-olanzapine. N = 112.
2. Olanzapine 5 mg IV + placebo-droperidol. N = 109.
3. Control group: placebo-droperidol, placebo-olanzapine. N = 115
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Chan 2013 (Continued)
Outcomes Global state: time to achieve adequate sedation for first time, need for additional par-
enteral sedative drugs, need for repeat sedationwithin 60minutes of initial sedation, total
midazolam dose administered in the 60 minutes after initial adequate sedation and from
60 minutes after initial adequate sedation until ED discharge, proportion adequately
sedated at 5 and 10 minutes after study drug administration
Service use: ED length of stay.
Adverse effects: corrected QT interval (QTc), need for airway management or assisted
ventilation, oxygen desaturation (90%)
Physiological: systolic blood pressure < 90 mmHg, dystonic reactions, seizures, vomiting
or aspiration, and movement disorders
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computerized block randomisa-
tion (blocks of 6), stratified by study site,
was performed by an independent pharma-
cist”
Response: randomisation probably done.
Allocation concealment (selection bias) Low risk Quote: “After enrolment, patients were as-
signed to the next study pack in the allo-
cated sequence”
Response: low risk of selection bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All patients, ED staff, and study
personnel remained blinded to group allo-
cation until data entry and analyses were
completed”
Response: low risk of performance bias.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The appearance of the drug vials
and the dosage instructions for the placebo
and active study drugs were identical”
Response: low risk of detection bias.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of 457 patients screened for eligi-
bility, 121 were excluded and 336 were en-
rolled. All groups had similar baseline char-
acteristics. Patients with minor protocol vi-
olations (mainly delays in initial midazo-
lam administration) were included in the
analysis. The nature of the violations did
not differ substantially between the groups”
Response: incomplete outcome data ad-
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Chan 2013 (Continued)
dressed.
Selective reporting (reporting bias) Low risk All the outcomes were adequately reported.
Cocchi 1971
Methods Allocation: Allocation: randomised - no further details.
Blinding: double (drugs packaging was indistinguishable; assessors were external doctors.
However, they discussed every clinical case with doctors involved in patients’ care)
Design: randomised (with same drug schedule - dose and duration - for almost all
randomised participants. 4 people in droperidol group did not receive the plateau dose
due to EPS)
Duration: 30 days.
Settings: hospital.
Participants Diagnosis: schizophrenia - acute exacerbation.
N = 40.
Age: range 17 to 51 years, median 25 years.
Sex: female 16, male 24.
History: psychiatric inpatients.
Excluded: no exclusions mentioned.
Interventions 1. Droperidol 2 mg to 10 mg orally. N = 20.
2. Haloperidol 2 mg to 10 mg orally. N = 20.
Outcomes Global state: clinical improvement.
Mental state: Rating Scale for Quantification of Psychotic Symptom Severity
Mental state: Specific Symptoms Scale (unpublished scale, specific symptoms - no stan-
dard deviation) - unable to use
Adverse effects: EPS (no data) - unable to use.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised - no details on how random
sequence was generated
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as “double-blind”, but ex-
ternal assessors and doctors involved in pa-
tient care discussed every case in order to
get a global evaluation of them
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Cocchi 1971 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information about data analysis (it
seems that rating scales were administered
4 times to all participants, but no details
reported)
Selective reporting (reporting bias) Unclear risk Data reported for outcomes listed in the
methods.
Knott 2006
Methods Allocation: randomised.
Blinding: double-blind.
Duration: 2 hours.
Settings: conducted in the ED of a large Australian metropolitan university hospital
Participants Diagnosis: marked agitation, required chemical restraint (about 66% ’mental illness’)
N = 170.
Age: range 18 to 65 years.
Sex: unspecified.
History: aged judged to be 18 to 65 years (inclusive), exhibited marked agitation that
required chemical restraint (decision of consultant (attending) emergency physician or
a senior accredited resident of the Australasian College for Emergency Medicine)
Excluded: people with known hypersensitivity to either drug, known pregnancy or read-
ily reversible causes for the agitation (systolic blood pressure < 90mmHg, hypoxia, hypo-
glycaemia). If treating physician believed agitation was due to acute alcohol withdrawal,
participant excluded because this condition is particularly amenable to treatment with
benzodiazepines
Interventions 1. Droperidol5 mg IV. N = 86.
2. Midazolam5 mg IV. N = 84.
Outcomes Global state: time to sedation, need for subsequent sedation within 60 minutes of initial
(adequate) sedation
Adverse effects: ECG, corrected QT (QTc) interval on a 12-lead ECG
Physiological: pulse rate, blood pressure, oxygen saturation
Loss to follow-up.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was determined
from random-number tables”
Response: randomisation probably done.
42Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Knott 2006 (Continued)
Allocation concealment (selection bias) Low risk Quote: “These solutions were packaged in
identical vials and randomly assigned to se-
rially numbered study packs”
Response: low risk of selection bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “patients and staff remained
blinded to which drug was used through-
out each patient’s stay”
Response: blinding probably practiced.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “and the codes remainedwith phar-
macy until the study was complete”
Response: blinding of the outcome assess-
ment probably done.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “One hundred seventy patients
were enrolled by study-pack allocation. Of
these, 17 packs were lost so that data on
153 patients were available for analysis”
Response: 17 study packs were lost. It is
unknown whether these were selected and
discarded unused or used for sedation, with
all documentation subsequently lost
Resnick 1984
Methods Allocation: unclear - ’code in pharmacy’, probably randomised
Design: unspecified.
Blinding: double - identical vials.
Duration: 24 hours (re-evaluated at 15 minutes after the initial injection and at 30
minute intervals for 3 hours)
Settings: ED and Psychiatric Crisis Unit, Oregon Health Sciences University, Portland
Participants Diagnosis: psychotic - unspecified.
N = 27.
Age: range 18 to 65 years.
Sex: unspecified.
History: admitted to ED of psychiatric unit with symptoms of acute agitation and
achieved a score of ≥ 17 on a subset of 6 categories on the BPRS
Excluded: people who were intoxicated; had known sensitivity to droperidol or haloperi-
dol; or showed evidence of active renal, hepatic or cardiac disease
Interventions 1. Droperidol5 mg IM. N = 11.
2. Haloperidol5 mg IM. N = 16.
Outcomes Global state: needing additional injection, time to control, BPRS
Adverse effects.
Adverse effects: EPS.
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Resnick 1984 (Continued)
Vital signs: blood pressure, pulse, respiration (no data) - unable to use
Notes Predefined levels of BPRS (subset - anxiety, tension, mannerisms and posturing, hostility,
unco-operativeness, excitement) to a score of > 15 used to instigate reinjection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...haloperidol on a randomised ba-
sis from identical appearing vials...”
Response: probably randomised.
Allocation concealment (selection bias) Unclear risk Quote: “Packages of medication were iden-
tified only by a code which was kept in the
pharmacy until the conclusion of the study.
”
Response: unclear whether and how alloca-
tion concealment was assured
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a double-blind clinical compari-
son of droperidol and haloperidol was un-
dertaken”
Response: personnel and participants were
probably blind to the interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if blinding of outcome assessment
was carried out.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 16 patients in the haloperi-
dol group, 3 required a single injection and
13 required two or more injections... In
droperidol group, 7 of the 11 patients re-
quired one injection and 4 required two in-
jection”
Response: low risk of attrition bias as
the number of people initially randomised
were all included in the final analysis
Selective reporting (reporting bias) Low risk All the stated outcomes were reported.
Other bias Unclear risk Unclear.
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Van Leeuwen 1977
Methods Allocation: randomly assigned - participants listed in chronological order assigned indi-
vidually numbered vials
Blinding: double - no further details.
Design: double-blind placebo-controlled study.
Duration: 30 minutes.
Settings: not clear.
Participants Diagnosis: schizophrenia (N = 20); mania/manic depression (N = 9), confusional state
(N = 2), miscellaneous (N = 3), not recorded (N = 7)
N = 41.
Age: range 14 to 78 years, median 33.5 years.
Sex: female 18, male 23.
History: acutely agitated, about 50% already taking maintenance psychotropic drugs,
about 20% already received inadequate treatment for agitation
Excluded: no exclusions mentioned.
Interventions 1. Droperidol 10 mg IV. N = 19.
2. Placebo 10 mg IV. N = 22.
Outcomes Global state: needing additional injection, time to control (no measure/scale given)
Adverse effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The vials containing this solution
were individually numbered and their con-
tent (droperidol or placebo) was randomly
assigned”
Response: probably randomised.
Allocation concealment (selection bias) Unclear risk Quote: “On entering the trial, the patients
were chronologically numbered and this
number indicated the vial which was to be
used”
Response: unclear method of concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the study was strictly double
blinded...”
Response: participants and personnel were
probably blind to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nomention of blinding of outcome assess-
ment.
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Van Leeuwen 1977 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “breaking the code revealed that 19
patients had been treated with droperidol
and 22 patients with placebo”
Response: all participants who were ini-
tially included were analysed
Selective reporting (reporting bias) Low risk All outcomes were reported.
BPRS: Brief Psychiatric Rating Scale; ECG: electrocardiogram; ED: emergency department; EPS: extrapyramidal adverse effects; IM:
intramuscular; IV: intravenous; SAT: Social Attribution Task.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cocito 1970 Allocation: randomised.
Participants: people with psychosis in hospital, not acutely ill
Fang 2014 Allocation: no information regarding randomisation.
Interventions: no mention of droperidol.
Foster 1995 Allocation: randomised.
Participants: healthy women attending day hospital for minor surgery
Girard 1972 Allocation: not randomised, case-control study.
Hooper 1983 Allocation: unclear; Dr Hooper kindly responded to email - allocation was quasi-randomised, “every other patient”
Hu 2014 Allocation: quasi-randomised.
Isbister 2010 Allocation: randomised.
Participants: people with violent and acute behavioural disturbance. No mention of any underlying psychiatric
illness
Lilburn 1977 Allocation: not randomised.
Richards 1997 Allocation: randomised.
Participants: people with methamphetamine toxicity, not people with severe mental illnesses
Richards 1998 Allocation: randomised.
Participants: mostly people with drug-induced toxicity (total 202), 20 with ’psychiatric illness’.
Interventions: droperidol vs. lorazepam.
Outcomes: sedation, re-admission, adverse effects, additional drugs, time in emergency department, vital signs - no
data exclusively for 20 people with ’psychiatric illness’
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(Continued)
Rosen 1997 Allocation: randomised.
Participants: mostly people with trauma and medical reasons for their disturbance (total 46), 1 with ’psychiatric’
diagnosis.
Interventions: droperidol vs. placebo.
Outcomes: sedation, re-admission, adverse effects, additional drugs, time in emergency department, vital signs - no
data exclusively for the person with ’psychiatric diagnosis’
Thomas 1992 Allocation: randomised.
Participants: mostly people who were intoxicated or had some form of underlying illness (trauma), no mention of
psychoses or psychiatric illness
Weiser 1973 Allocation: not randomised, case series.
Weiser 1975 Allocation: randomly assigned.
Participants: people with schizophrenia - acute/subacute (N = 50 but 5 added during study).
Interventions: droperidol 100 mg vs. droperidol 150 mg vs. droperidol 200 mg vs. clopenthixol vs. clozapine.
Outcomes: behaviour, mental state, length of stay in hospital, leaving the study early - but not presented free of
data from 5 non-random additional participants
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D A T A A N D A N A L Y S E S
Comparison 1. Droperidol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
tranquillised/sleep
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 By 5 minutes 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.90, 1.96]
1.2 By 10 minutes 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.08, 1.71]
1.3 By 30 minutes 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.05, 1.31]
1.4 By 60 minutes 1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [1.00, 1.18]
2 Tranquillisation or asleep:
2. difficulty in achieving
tranquillisation/sleep
1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.75]
3 Tranquillisation or asleep: 3.
time to tranquillisation/sleep
(minutes)
1 227 Mean Difference (IV, Fixed, 95% CI) -46.5 [-86.83, -6.17]
4 Global state: use of additional
medication
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 “To reach initial adequate
sedation”
1 227 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.28, 0.89]
4.2 By 3 minutes (haloperidol) 1 41 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.18, 0.72]
4.3 By 30 minutes (any
psychotropic drug)
1 41 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.17, 1.24]
4.4 By 60 minutes
(midazolam, droperidol,
olanzapine, haloperidol)
1 227 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.42, 0.96]
4.5 By 60 minutes after
initial adequate sedation
until emergency department
discharge (various psychotropic
drugs)
1 227 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.36, 0.85]
5 Adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Cardiovascular -
arrhythmia
1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.31]
5.2 Cardiovascular -
hypotension
1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.20, 2.36]
5.3 Central nervous system
- oversedation (decreased
Glasgow Coma Score of 6)
1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.31]
5.4 Respiratory - airway
obstruction
1 227 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.15, 2.52]
5.5 Respiratory - oxygen
desaturation
1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.42, 2.49]
5.6 Unspecified - by 3 minutes 1 41 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Service use: 1 person able to be
discharged home
1 227 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.90, 1.48]
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7 Service use: 2 emergency
department length of stay
Other data No numeric data
Comparison 2. Droperidol versus haloperidol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
tranquillised/sleep within 120
minutes
1 228 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.93, 1.09]
2 Tranquillisation or asleep: 2.
time to tranquillisation/sleep
Other data No numeric data
3 Global state: use of additional
medication
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Midazolam administered
initially
1 228 Risk Ratio (M-H, Random, 95% CI) 3.26 [0.69, 15.37]
3.2 By 30 minutes 1 27 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.20, 1.01]
3.3 By 60 minutes 2 255 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.16, 0.90]
3.4 By 90 minutes 1 27 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.02, 10.63]
4 Global state: no overall
improvement - by 30 days
1 40 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.29, 1.52]
5 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Cardiovascular -
hypotension
1 228 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [0.30, 26.49]
5.2 Cardiovascular -
hypotension/desaturation
1 228 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [0.12, 67.98]
5.3 Central nervous system -
extrapyramidal adverse effects
1 228 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [0.12, 67.98]
5.4 Central nervous system -
oversedation
1 228 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [0.12, 67.98]
5.5 Staff injuries 1 228 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.14, 2.29]
6 Mental state: Average score by 13
days (Scale for Quantification
of Psychotic Symptom Severity,
high = poor)
1 40 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.07, 0.29]
Comparison 3. Droperidol versus midazolam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
tranquillised/asleep
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 5 minutes 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.21, 0.64]
1.2 At 10 minutes 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.72, 1.28]
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2 Tranquillisation or asleep: 2 time
to tranquillisation/sleep
Other data No numeric data
3 Global state: use of additional
medication
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.24, 1.20]
3.1 By 60 minutes 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.24, 1.20]
4 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Cardiovascular -
arrhythmia (bradycardia)
1 153 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.12, 67.98]
4.2 Cardiovascular -
hypotension
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.16, 3.03]
4.3 Central nervous system -
dystonic reaction
1 153 Risk Ratio (M-H, Fixed, 95% CI) 6.56 [0.34, 124.93]
4.4 Central nervous system -
seizure
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Gastric - aspiration 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Gastric - vomiting 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Respiratory - airway
management
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.55]
4.8 Respiratory - assistance
with ventilation
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Respiratory - hypoxia 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.16, 3.03]
Comparison 4. Droperidol versus olanzapine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
tranquillised/asleep
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 5 minutes 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.70, 1.42]
1.2 At 10 minutes 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.81, 1.17]
1.3 At 30 minutes 1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.94, 1.11]
1.4 At 60 minutes 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.93, 1.05]
2 Tranquillisation or asleep:
2. difficulty in achieving
tranquillisation/sleep
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.11, 3.81]
3 Tranquillisation or asleep: 3.
time to tranquillisation/sleep
(minutes)
1 221 Mean Difference (IV, Fixed, 95% CI) 7.30 [-11.74, 26.34]
4 Global state: use of additional
medication
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ’To reach initial adequate
sedation“
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.36, 1.28]
4.2 By 60 minutes
(midazolam, droperidol,
olanzapine, haloperidol)
1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.63, 1.64]
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4.3 From 60 minutes after
initial adequate sedation
until emergency department
discharge (various psychotropic
drugs)
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.36, 0.87]
5 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Cardiovascular -
arrhythmia
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.88]
5.2 Cardiovascular -
hypotension
1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.30, 5.66]
5.3 Central nervous system -
decreased Glasgow Coma Score
of 6
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Respiratory - airway
obstruction
1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.20, 4.72]
5.5 Respiratory - oxygen
desaturation
1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.61, 5.06]
6 Service use: 1. person able to be
discharged home
1 221 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.83, 1.34]
7 Service use: 2. emergency
department length of stay
Other data No numeric data
Analysis 1.1. Comparison 1 Droperidol versus placebo, Outcome 1 Tranquillisation or asleep: 1.
tranquillised/sleep.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 1 Tranquillisation or asleep: 1. tranquillised/sleep
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 By 5 minutes
Chan 2013 40/112 31/115 100.0 % 1.32 [ 0.90, 1.96 ]
Subtotal (95% CI) 112 115 100.0 % 1.32 [ 0.90, 1.96 ]
Total events: 40 (Droperidol), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 By 10 minutes
Chan 2013 74/112 56/115 100.0 % 1.36 [ 1.08, 1.71 ]
Subtotal (95% CI) 112 115 100.0 % 1.36 [ 1.08, 1.71 ]
Total events: 74 (Droperidol), 56 (Placebo)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours droperidol Favours placebo
(Continued . . . )
51Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.60 (P = 0.0093)
3 By 30 minutes
Chan 2013 103/112 90/115 100.0 % 1.18 [ 1.05, 1.31 ]
Subtotal (95% CI) 112 115 100.0 % 1.18 [ 1.05, 1.31 ]
Total events: 103 (Droperidol), 90 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0043)
4 By 60 minutes
Chan 2013 106/112 100/115 100.0 % 1.09 [ 1.00, 1.18 ]
Subtotal (95% CI) 112 115 100.0 % 1.09 [ 1.00, 1.18 ]
Total events: 106 (Droperidol), 100 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Chi2 = 4.25, df = 3 (P = 0.24), I2 =29%
0.01 0.1 1 10 100
Favours droperidol Favours placebo
Analysis 1.2. Comparison 1 Droperidol versus placebo, Outcome 2 Tranquillisation or asleep: 2. difficulty in
achieving tranquillisation/sleep.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chan 2013 2/112 4/115 100.0 % 0.51 [ 0.10, 2.75 ]
Total (95% CI) 112 115 100.0 % 0.51 [ 0.10, 2.75 ]
Total events: 2 (Droperidol), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours droperidol Favours placebo
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Analysis 1.3. Comparison 1 Droperidol versus placebo, Outcome 3 Tranquillisation or asleep: 3. time to
tranquillisation/sleep (minutes).
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes)
Study or subgroup Droperidol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chan 2013 112 21.3 (97.1) 115 67.8 (197.5) 100.0 % -46.50 [ -86.83, -6.17 ]
Total (95% CI) 112 115 100.0 % -46.50 [ -86.83, -6.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours droperidol Favours placebo
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Analysis 1.4. Comparison 1 Droperidol versus placebo, Outcome 4 Global state: use of additional
medication.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 4 Global state: use of additional medication
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ”To reach initial adequate sedation”
Chan 2013 14/112 29/115 100.0 % 0.50 [ 0.28, 0.89 ]
Subtotal (95% CI) 112 115 100.0 % 0.50 [ 0.28, 0.89 ]
Total events: 14 (Droperidol), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
2 By 3 minutes (haloperidol)
Van Leeuwen 1977 6/19 19/22 100.0 % 0.37 [ 0.18, 0.72 ]
Subtotal (95% CI) 19 22 100.0 % 0.37 [ 0.18, 0.72 ]
Total events: 6 (Droperidol), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0039)
3 By 30 minutes (any psychotropic drug)
Van Leeuwen 1977 4/19 10/22 100.0 % 0.46 [ 0.17, 1.24 ]
Subtotal (95% CI) 19 22 100.0 % 0.46 [ 0.17, 1.24 ]
Total events: 4 (Droperidol), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
4 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)
Chan 2013 26/112 42/115 100.0 % 0.64 [ 0.42, 0.96 ]
Subtotal (95% CI) 112 115 100.0 % 0.64 [ 0.42, 0.96 ]
Total events: 26 (Droperidol), 42 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
5 By 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs)
Chan 2013 23/112 43/115 100.0 % 0.55 [ 0.36, 0.85 ]
Subtotal (95% CI) 112 115 100.0 % 0.55 [ 0.36, 0.85 ]
Total events: 23 (Droperidol), 43 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0068)
0.1 0.2 0.5 1 2 5 10
Favours droperidol Favours placebo
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Analysis 1.5. Comparison 1 Droperidol versus placebo, Outcome 5 Adverse effects.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 5 Adverse effects
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cardiovascular - arrhythmia
Chan 2013 0/112 1/115 100.0 % 0.34 [ 0.01, 8.31 ]
Subtotal (95% CI) 112 115 100.0 % 0.34 [ 0.01, 8.31 ]
Total events: 0 (Droperidol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Cardiovascular - hypotension
Chan 2013 4/112 6/115 100.0 % 0.68 [ 0.20, 2.36 ]
Subtotal (95% CI) 112 115 100.0 % 0.68 [ 0.20, 2.36 ]
Total events: 4 (Droperidol), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 Central nervous system - oversedation (decreased Glasgow Coma Score of 6)
Chan 2013 0/112 1/115 100.0 % 0.34 [ 0.01, 8.31 ]
Subtotal (95% CI) 112 115 100.0 % 0.34 [ 0.01, 8.31 ]
Total events: 0 (Droperidol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
4 Respiratory - airway obstruction
Chan 2013 3/112 5/115 100.0 % 0.62 [ 0.15, 2.52 ]
Subtotal (95% CI) 112 115 100.0 % 0.62 [ 0.15, 2.52 ]
Total events: 3 (Droperidol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
5 Respiratory - oxygen desaturation
Chan 2013 9/112 9/115 100.0 % 1.03 [ 0.42, 2.49 ]
Subtotal (95% CI) 112 115 100.0 % 1.03 [ 0.42, 2.49 ]
Total events: 9 (Droperidol), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
6 Unspecified - by 3 minutes
Van Leeuwen 1977 0/19 0/22 Not estimable
Subtotal (95% CI) 19 22 Not estimable
Total events: 0 (Droperidol), 0 (Placebo)
0.01 0.1 1 10 100
Favours droperidol Favours placebo
(Continued . . . )
55Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.03, df = 4 (P = 0.90), I2 =0.0%
0.01 0.1 1 10 100
Favours droperidol Favours placebo
Analysis 1.6. Comparison 1 Droperidol versus placebo, Outcome 6 Service use: 1 person able to be
discharged home.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 1 Droperidol versus placebo
Outcome: 6 Service use: 1 person able to be discharged home
Study or subgroup Droperidol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chan 2013 63/112 56/115 100.0 % 1.16 [ 0.90, 1.48 ]
Total (95% CI) 112 115 100.0 % 1.16 [ 0.90, 1.48 ]
Total events: 63 (Droperidol), 56 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours droperidol Favours placebo
Analysis 1.7. Comparison 1 Droperidol versus placebo, Outcome 7 Service use: 2 emergency department
length of stay.
Service use: 2 emergency department length of stay
Study Intervention number of participants Median (hours) Interquartile range
Chan 2013 Droperidol 112 10.0 6.7 to 13.2
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Service use: 2 emergency department length of stay (Continued)
Chan 2013 Placebo 115 9.7 5.7 to 14.7
Analysis 2.1. Comparison 2 Droperidol versus haloperidol, Outcome 1 Tranquillisation or asleep: 1.
tranquillised/sleep within 120 minutes.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 2 Droperidol versus haloperidol
Outcome: 1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes
Study or subgroup Droperidol Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Calver 2015 109/118 101/110 100.0 % 1.01 [ 0.93, 1.09 ]
Total (95% CI) 118 110 100.0 % 1.01 [ 0.93, 1.09 ]
Total events: 109 (Droperidol), 101 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours droperidol Favours haloperidol
Analysis 2.2. Comparison 2 Droperidol versus haloperidol, Outcome 2 Tranquillisation or asleep: 2. time to
tranquillisation/sleep.
Tranquillisation or asleep: 2. time to tranquillisation/sleep
Study Intervention Number of participants Median (minutes) Interquartile range
Calver 2015 Droperidol 118 25 15 to 30
Calver 2015 Haloperidol 110 20 15 to 30
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Analysis 2.3. Comparison 2 Droperidol versus haloperidol, Outcome 3 Global state: use of additional
medication.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 2 Droperidol versus haloperidol
Outcome: 3 Global state: use of additional medication
Study or subgroup Droperidol Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Midazolam administered initially
Calver 2015 7/118 2/110 100.0 % 3.26 [ 0.69, 15.37 ]
Subtotal (95% CI) 118 110 100.0 % 3.26 [ 0.69, 15.37 ]
Total events: 7 (Droperidol), 2 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
2 By 30 minutes
Resnick 1984 4/11 13/16 100.0 % 0.45 [ 0.20, 1.01 ]
Subtotal (95% CI) 11 16 100.0 % 0.45 [ 0.20, 1.01 ]
Total events: 4 (Droperidol), 13 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
3 By 60 minutes
Calver 2015 6/118 14/110 90.7 % 0.40 [ 0.16, 1.00 ]
Resnick 1984 0/11 3/16 9.3 % 0.20 [ 0.01, 3.57 ]
Subtotal (95% CI) 129 126 100.0 % 0.37 [ 0.16, 0.90 ]
Total events: 6 (Droperidol), 17 (Haloperidol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
4 By 90 minutes
Resnick 1984 0/11 1/16 100.0 % 0.47 [ 0.02, 10.63 ]
Subtotal (95% CI) 11 16 100.0 % 0.47 [ 0.02, 10.63 ]
Total events: 0 (Droperidol), 1 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
0.001 0.01 0.1 1 10 100 1000
Favours droperidol Favours haloperidol
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Analysis 2.4. Comparison 2 Droperidol versus haloperidol, Outcome 4 Global state: no overall
improvement - by 30 days.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 2 Droperidol versus haloperidol
Outcome: 4 Global state: no overall improvement - by 30 days
Study or subgroup Droperidol Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cocchi 1971 6/20 9/20 100.0 % 0.67 [ 0.29, 1.52 ]
Total (95% CI) 20 20 100.0 % 0.67 [ 0.29, 1.52 ]
Total events: 6 (Droperidol), 9 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Droperidol versus haloperidol, Outcome 5 Adverse effects.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 2 Droperidol versus haloperidol
Outcome: 5 Adverse effects
Study or subgroup Droperidol Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cardiovascular - hypotension
Calver 2015 3/118 1/110 100.0 % 2.80 [ 0.30, 26.49 ]
Subtotal (95% CI) 118 110 100.0 % 2.80 [ 0.30, 26.49 ]
Total events: 3 (Droperidol), 1 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
2 Cardiovascular - hypotension/desaturation
Calver 2015 1/118 0/110 100.0 % 2.80 [ 0.12, 67.98 ]
Subtotal (95% CI) 118 110 100.0 % 2.80 [ 0.12, 67.98 ]
Total events: 1 (Droperidol), 0 (Haloperidol)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours droperidol Favours haloperidol
(Continued . . . )
59Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Droperidol Haloperidol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.63 (P = 0.53)
3 Central nervous system - extrapyramidal adverse effects
Calver 2015 1/118 0/110 100.0 % 2.80 [ 0.12, 67.98 ]
Subtotal (95% CI) 118 110 100.0 % 2.80 [ 0.12, 67.98 ]
Total events: 1 (Droperidol), 0 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
4 Central nervous system - oversedation
Calver 2015 1/118 0/110 100.0 % 2.80 [ 0.12, 67.98 ]
Subtotal (95% CI) 118 110 100.0 % 2.80 [ 0.12, 67.98 ]
Total events: 1 (Droperidol), 0 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
5 Staff injuries
Calver 2015 3/118 5/110 100.0 % 0.56 [ 0.14, 2.29 ]
Subtotal (95% CI) 118 110 100.0 % 0.56 [ 0.14, 2.29 ]
Total events: 3 (Droperidol), 5 (Haloperidol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 2.48, df = 4 (P = 0.65), I2 =0.0%
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Analysis 2.6. Comparison 2 Droperidol versus haloperidol, Outcome 6 Mental state: Average score by 13
days (Scale for Quantification of Psychotic Symptom Severity, high = poor).
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 2 Droperidol versus haloperidol
Outcome: 6 Mental state: Average score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor)
Study or subgroup Droperidol Haloperidol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cocchi 1971 20 3.48 (0.27) 20 3.37 (0.31) 100.0 % 0.11 [ -0.07, 0.29 ]
Total (95% CI) 20 20 100.0 % 0.11 [ -0.07, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Droperidol versus midazolam, Outcome 1 Tranquillisation or asleep: 1.
tranquillised/asleep.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 3 Droperidol versus midazolam
Outcome: 1 Tranquillisation or asleep: 1. tranquillised/asleep
Study or subgroup Droperidol Midazolam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 5 minutes
Knott 2006 13/79 33/74 100.0 % 0.37 [ 0.21, 0.64 ]
Subtotal (95% CI) 79 74 100.0 % 0.37 [ 0.21, 0.64 ]
Total events: 13 (Droperidol), 33 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00046)
2 At 10 minutes
Knott 2006 42/79 41/74 100.0 % 0.96 [ 0.72, 1.28 ]
Subtotal (95% CI) 79 74 100.0 % 0.96 [ 0.72, 1.28 ]
Total events: 42 (Droperidol), 41 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 8.86, df = 1 (P = 0.00), I2 =89%
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Analysis 3.2. Comparison 3 Droperidol versus midazolam, Outcome 2 Tranquillisation or asleep: 2 time to
tranquillisation/sleep.
Tranquillisation or asleep: 2 time to tranquillisation/sleep
Study Intervention Number of participants Median (minutes)
Knott 2006 Droperidol 79 8
Knott 2006 Midazolam 74 6.5
Analysis 3.3. Comparison 3 Droperidol versus midazolam, Outcome 3 Global state: use of additional
medication.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 3 Droperidol versus midazolam
Outcome: 3 Global state: use of additional medication
Study or subgroup Droperidol Midazolam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 By 60 minutes
Knott 2006 8/79 14/74 100.0 % 0.54 [ 0.24, 1.20 ]
Total (95% CI) 79 74 100.0 % 0.54 [ 0.24, 1.20 ]
Total events: 8 (Droperidol), 14 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Droperidol versus midazolam, Outcome 4 Adverse effects.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 3 Droperidol versus midazolam
Outcome: 4 Adverse effects
Study or subgroup Droperidol Midazolam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cardiovascular - arrhythmia (bradycardia)
Knott 2006 1/79 0/74 100.0 % 2.81 [ 0.12, 67.98 ]
Subtotal (95% CI) 79 74 100.0 % 2.81 [ 0.12, 67.98 ]
Total events: 1 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Cardiovascular - hypotension
Knott 2006 3/79 4/74 100.0 % 0.70 [ 0.16, 3.03 ]
Subtotal (95% CI) 79 74 100.0 % 0.70 [ 0.16, 3.03 ]
Total events: 3 (Droperidol), 4 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Central nervous system - dystonic reaction
Knott 2006 3/79 0/74 100.0 % 6.56 [ 0.34, 124.93 ]
Subtotal (95% CI) 79 74 100.0 % 6.56 [ 0.34, 124.93 ]
Total events: 3 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
4 Central nervous system - seizure
Knott 2006 0/79 0/74 Not estimable
Subtotal (95% CI) 79 74 Not estimable
Total events: 0 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Gastric - aspiration
Knott 2006 0/79 0/74 Not estimable
Subtotal (95% CI) 79 74 Not estimable
Total events: 0 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Gastric - vomiting
Knott 2006 0/79 0/74 Not estimable
Subtotal (95% CI) 79 74 Not estimable
Total events: 0 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Droperidol Midazolam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: not applicable
7 Respiratory - airway management
Knott 2006 0/79 3/74 100.0 % 0.13 [ 0.01, 2.55 ]
Subtotal (95% CI) 79 74 100.0 % 0.13 [ 0.01, 2.55 ]
Total events: 0 (Droperidol), 3 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
8 Respiratory - assistance with ventilation
Knott 2006 0/79 0/74 Not estimable
Subtotal (95% CI) 79 74 Not estimable
Total events: 0 (Droperidol), 0 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Respiratory - hypoxia
Knott 2006 3/79 4/74 100.0 % 0.70 [ 0.16, 3.03 ]
Subtotal (95% CI) 79 74 100.0 % 0.70 [ 0.16, 3.03 ]
Total events: 3 (Droperidol), 4 (Midazolam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 4.03, df = 4 (P = 0.40), I2 =1%
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Analysis 4.1. Comparison 4 Droperidol versus olanzapine, Outcome 1 Tranquillisation or asleep: 1.
tranquillised/asleep.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 1 Tranquillisation or asleep: 1. tranquillised/asleep
Study or subgroup Droperidol Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 5 minutes
Chan 2013 40/112 39/109 100.0 % 1.00 [ 0.70, 1.42 ]
Subtotal (95% CI) 112 109 100.0 % 1.00 [ 0.70, 1.42 ]
Total events: 40 (Droperidol), 39 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 At 10 minutes
Chan 2013 74/112 74/109 100.0 % 0.97 [ 0.81, 1.17 ]
Subtotal (95% CI) 112 109 100.0 % 0.97 [ 0.81, 1.17 ]
Total events: 74 (Droperidol), 74 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
3 At 30 minutes
Chan 2013 103/112 98/109 100.0 % 1.02 [ 0.94, 1.11 ]
Subtotal (95% CI) 112 109 100.0 % 1.02 [ 0.94, 1.11 ]
Total events: 103 (Droperidol), 98 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
4 At 60 minutes
Chan 2013 106/112 104/109 100.0 % 0.99 [ 0.93, 1.05 ]
Subtotal (95% CI) 112 109 100.0 % 0.99 [ 0.93, 1.05 ]
Total events: 106 (Droperidol), 104 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.43, df = 3 (P = 0.93), I2 =0.0%
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Analysis 4.2. Comparison 4 Droperidol versus olanzapine, Outcome 2 Tranquillisation or asleep: 2. difficulty
in achieving tranquillisation/sleep.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep
Study or subgroup Droperidol Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chan 2013 2/112 3/109 100.0 % 0.65 [ 0.11, 3.81 ]
Total (95% CI) 112 109 100.0 % 0.65 [ 0.11, 3.81 ]
Total events: 2 (Droperidol), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Droperidol versus olanzapine, Outcome 3 Tranquillisation or asleep: 3. time to
tranquillisation/sleep (minutes).
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes)
Study or subgroup Droperidol Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chan 2013 112 21.3 (97.1) 109 14 (33.3) 100.0 % 7.30 [ -11.74, 26.34 ]
Total (95% CI) 112 109 100.0 % 7.30 [ -11.74, 26.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Droperidol versus olanzapine, Outcome 4 Global state: use of additional
medication.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 4 Global state: use of additional medication
Study or subgroup Droperidol Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ’To reach initial adequate sedation”
Chan 2013 14/112 20/109 100.0 % 0.68 [ 0.36, 1.28 ]
Subtotal (95% CI) 112 109 100.0 % 0.68 [ 0.36, 1.28 ]
Total events: 14 (Droperidol), 20 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)
Chan 2013 26/112 25/109 100.0 % 1.01 [ 0.63, 1.64 ]
Subtotal (95% CI) 112 109 100.0 % 1.01 [ 0.63, 1.64 ]
Total events: 26 (Droperidol), 25 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 From 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs)
Chan 2013 23/112 40/109 100.0 % 0.56 [ 0.36, 0.87 ]
Subtotal (95% CI) 112 109 100.0 % 0.56 [ 0.36, 0.87 ]
Total events: 23 (Droperidol), 40 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Chi2 = 3.21, df = 2 (P = 0.20), I2 =38%
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Analysis 4.5. Comparison 4 Droperidol versus olanzapine, Outcome 5 Adverse effects.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 5 Adverse effects
Study or subgroup Droperidol Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cardiovascular - arrhythmia
Chan 2013 0/112 1/109 100.0 % 0.32 [ 0.01, 7.88 ]
Subtotal (95% CI) 112 109 100.0 % 0.32 [ 0.01, 7.88 ]
Total events: 0 (Droperidol), 1 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Cardiovascular - hypotension
Chan 2013 4/112 3/109 100.0 % 1.30 [ 0.30, 5.66 ]
Subtotal (95% CI) 112 109 100.0 % 1.30 [ 0.30, 5.66 ]
Total events: 4 (Droperidol), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 Central nervous system - decreased Glasgow Coma Score of 6
Chan 2013 0/112 0/109 Not estimable
Subtotal (95% CI) 112 109 Not estimable
Total events: 0 (Droperidol), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Respiratory - airway obstruction
Chan 2013 3/112 3/109 100.0 % 0.97 [ 0.20, 4.72 ]
Subtotal (95% CI) 112 109 100.0 % 0.97 [ 0.20, 4.72 ]
Total events: 3 (Droperidol), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
5 Respiratory - oxygen desaturation
Chan 2013 9/112 5/109 100.0 % 1.75 [ 0.61, 5.06 ]
Subtotal (95% CI) 112 109 100.0 % 1.75 [ 0.61, 5.06 ]
Total events: 9 (Droperidol), 5 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 1.16, df = 3 (P = 0.76), I2 =0.0%
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Analysis 4.6. Comparison 4 Droperidol versus olanzapine, Outcome 6 Service use: 1. person able to be
discharged home.
Review: Droperidol for psychosis-induced aggression or agitation
Comparison: 4 Droperidol versus olanzapine
Outcome: 6 Service use: 1. person able to be discharged home
Study or subgroup Droperidol Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chan 2013 63/112 58/109 100.0 % 1.06 [ 0.83, 1.34 ]
Total (95% CI) 112 109 100.0 % 1.06 [ 0.83, 1.34 ]
Total events: 63 (Droperidol), 58 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Droperidol versus olanzapine, Outcome 7 Service use: 2. emergency
department length of stay.
Service use: 2. emergency department length of stay
Study Intervention Number of participants Median (hours) Interquartile range
Chan 2013 Droperidol 112 10.0 6.7 to 13.2
Chan 2013 Olanzapine 109 11.0 7.2 to 14.7
A D D I T I O N A L T A B L E S
Table 1. Survey of 20 medical directors of emergency departments in the USA
Favoured drug Number
Haloperidol + lorazepam ± benztropine 11
Droperidol 4
Benzodiazepine (unspecified) alone 3
Droperidol + lorazepam + diphenhydramine 1
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Table 1. Survey of 20 medical directors of emergency departments in the USA (Continued)
Haloperidol + benztropine 1
Table 2. Preferred medication for rapid tranquillisation in Rio de Janeiro
Drug of choice Mean dose (mg) Frequency of use
Haloperidol + promethazine 5 (2.5 to 10) + 50 (25 to 100) 61%
Haloperidol + promethazine + diazepam 5 (2.5 to 10) + 50 (25 to 100) +10 15%
Diazepam 10 9%
Haloperidol + promethazine + chlorpro-
mazine
5 + 50 + 25 7%
Chlorpromazine + diazepam + promet-
hazine
25 + 10 + 50 1%
Chlorpromazine + promethazine 25 + 50 1%
Chlorpromazine 25 1%
Diazepam + promethazine 10 + 50 1%
Haloperidol + diazepam 5 + 10 1%
Promethazine 50 1%
Table 3. Drugs for rapid tranquillisation in London survey
Drug of choice Mean dose (mg)
Diazepam* 27 (10 to 80)
Haloperidol 22 (10 to 60)
Chlorpromazine 162 (50 to 400)
Droperidol 14 (10 to 20)
Paraldehyde U/K
Amytal U/K
Lorazepam U/K
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Table 3. Drugs for rapid tranquillisation in London survey (Continued)
Nitrazepam** U/K
* most frequent; **least frequent; U/K: unknown.
Table 4. Other relevant Cochrane reviews
Focus of review Reference
Completed and maintained reviews
’As required’ medication regimens for seriously mentally ill people
in hospital
Chakrabarti 2007
Benzodiazepines for psychosis-induced aggression or agitation Gillies 2005
Chlorpromazine for psychosis-induced aggression or agitation Ahmed 2010
Clotiapine for acute psychotic illnesses Berk 2004
Containment strategies for people with serious mental illness Muralidharan 2006
Droperidol for acute psychosis This review
Haloperidol for psychosis-induced aggression or agitation (rapid
tranquillisation)
Powney 2012
Haloperidol + promethazine for psychosis-induced aggression Huf 2009
Olanzapine IM or olanzapine orodispersible tablet for acutely dis-
turbed/agitated people with suspected serious mental illnesses
Belgamwar 2005
Seclusion and restraint for serious mental illnesses Sailas 2000
Zuclopenthixol acetate for acute schizophrenia and similar serious
mental illnesses
Gibson 2004
Reviews in the process of being completed or updated
Risperidone for psychosis-induced aggression or agitation Ahmed 2011
Haloperidol for long-term aggression in psychosis Khushu 2012
Loxapine inhaler for psychosis-induced aggression Vangala 2012
Clozapine for people with schizophrenia and recurrent physical
aggression (Title)
Toal 2012
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Table 4. Other relevant Cochrane reviews (Continued)
Quetiapine for psychosis-induced aggression Wilkie 2012
De-escalation techniques for psychosis-induced aggression Rao 2012
IM: intramuscular.
Table 5. Length of included studies
Study Immediate (< 2 hours) Short term (> 2 hours to
24 hours)
Medium term (> 24
hours to 2 weeks)
Long term (> 2 weeks)
Van Leeuwen 1977
√
(3 and 30 min) - - -
Chan 2013
√
(5, 10 and 60 min) - - -
Calver 2015
√
(10 min)
√
(120 min) - -
Knott 2006
√
(within 60 min)
√
(2 hours) - -
Resnick 1984
√
(15 and 30 min)
√
(24 hours) - -
Cocchi 1971 - - -
√
(30 days)
min: minute.
Table 6. Randomised excluded studies relevant to other reviews
Excluded study Participants Suggested comparison Existing review
People with serious
mental illness
People without mental
illness
Hu 2014 Acute agitation and
schizophrenia.
- Haloperidol vs. ziprasi-
done for acute agitation
and schizophrenia
Powney 2012
Cocito 1970 With psychosis in hospi-
tal, not acutely ill.
Droperidol for (non-
acute) psychosis.
-
Isbister 2010; Rosen
1997
- People with violent and
acute behavioural distur-
bance. No mention of
any underlying psychi-
atric illness
Droperidol
for acute non-psychiatric
disturbance.
-
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Table 6. Randomised excluded studies relevant to other reviews (Continued)
Mostly people
with trauma andmedical
reasons for their distur-
bance (total 46), 1 with
’psychiatric’ diagnosis
Richards 1997; Richards
1998;
Thomas 1992
People
with drug-induced toxi-
city, not people with se-
vere mental illnesses
Droperidol for drug-in-
duced toxicity.
-
Foster 1995 Healthy women attend-
ing day hospital for mi-
nor surgery.
Droperidol for minor
surgery.
-
Table 7. Design of a future study
Methods Allocation: randomised (clearly described).
Blinding: single blind (outcomes assessor).
Duration: up to 2 weeks.
Design: parallel.
Setting: emergency settings.
Participants Diagnosis: people whose aggressive behaviour is thought due to psychotic illness
N = 300.
Age: > 18 years.
Sex: not applicable.
Inclusion criteria: other measures failed.
Exclusion criteria: specific contraindication to evaluated treatments
Interventions 1. Droperidol. N = 150.
2. Drug intervention of choice. N = 150.
Both drugs should be known to be effective, but the comparative effectiveness be unclear
Outcomes Tranquil/asleep: binary outcomes, time.
Behaviour: need for additional medication, additional aggressive episode
Adverse effects.
Acceptability of treatment.
Costs: cost of services, cost of care.
Quality of life.
Service outcomes: days in hospital, discharged, transfer to secure unit
Notes Study should comply with CONSORT and AllTrials.
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A P P E N D I C E S
Appendix 1. Previous searches
1.1 Searches in 1998 to 2000
This review is part of a larger project attempting to identify all randomised trials relevant to the management of aggressive or violent
people. The searches are therefore more general than would be expected for such a review (see 2.6).
1.1.1 Electronic searches
1.1.1.1 AMED (1983 to December 1998)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate* or
correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or ”ANGER-“ in SH or ”AGGRESSION-
“ in SH or explode ”CRIME“ or ”EXHIBITIONISM-“ in SH or ”JUVENILE-DELINQUENCY“ in SH or ”PRISONS-“ in SH or
”PRISONERS-“ in SH or explode ”VIOLENCE“)
1.1.1.2 ASSIA (1987 to December 1998)
randomi* or random* and allocat* or random* and assign* or singl* blind* or doubl* blind* or tripl* blind* or trebl* blind*
The resulting records were then searched in ProCite using the phrase:
homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or assault* or assail* or attacker* or ((physical or spouse
or elder or sexual* or child or partner) and abus*) or rape* or rapist* or bugger* or sodom* or molest* or pedophil* or paedophil*
or indecen* or exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* or
hostil* or cruel* or delinquen* or threaten* or disorderly or affray* or felon* or unlawful* or penal* or penol* or crim* or offen* or
prison* or inmate* or correctional* or firearm* or weapon* or gun* or (intent and (kill or harm)) or (bodily and harm) or (child and
neglect) or masturbat* or (breach* and peace) or (dangerous and (behav* or histor* or conduct*)) or (disrupt* and (behav* or histor*
or conduct*)) or ((destruct* and not self-destruc*) and (behav* or histor* or conduct*)) or ((anti-social or antisocial) and (behav* or
histor* or conduct*)) or agitat*
1.1.1.3 Biological Abstracts (1993 to September 1999) and BA on CD (1982 to 1985)
They were searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat*)
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1.1.1.4 Brainwave (Pharmaceutical Newsletters, Pharmaceutical Research, Pharmaceutical Industry News, Social Sciences,
Medical Research)
It was searched on the internet (http://www.brainwave.telebase.com [Searched on May 5, 2000]) using the phrase:
((random* or doubl*) and aggress*) or ((random* or doubl*) and violen*) within the title field
1.1.1.5 British Nursing Index/RCN Journals (1988 to September 1999)
They were searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat*)
1.1.1.6 Cambridge Scientific Abstracts (1982 to January 2000)
It was searched using the phrase:
(homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or assault* or assail* or attacker* or ((physical or spouse
or elder or sexual* or child or partner) and abus*) or rape* or rapist* or bugger* or sodom* or molest* or pedophil* or paedophil*
or indecen* or exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* or
hostil* or cruel* or delinquen* or threaten* or disorderly or affray* or felon* or unlawful* or penal* or penol* or crim* or offen* or
prison* or inmate* or correctional* or firearm* or weapon* or gun* or (intent and (kill or harm)) or (bodily and harm) or (child and
neglect) or masturbat* or (breach* and peace) or (dangerous and (behav* or histor* or conduct*)) or (disrupt* and (behav* or histor*
or conduct*)) or ((destruct* and not self-destruc*) and (behav* or histor* or conduct*)) or ((anti-social or antisocial) and (behav* or
histor* or conduct*))) or agitat* and (randomi* or (random* and alloc*) or (random* and assign*) or (doubl* and blind))
1.1.1.7 CINAHL (1982 to October 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1
harm or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in
ab or child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual*
abus* in ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or
lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or
(dangerous or disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor*
or conduct*) or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or
affray* or breach* near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in
ab or prison* or inmate* or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or ”Anal-
Intercourse“/ all topical subheadings / all age subheadings or explode ”Aggression“/ all topical subheadings / all age subheadings or
explode ”Public-Offenders“/ all topical subheadings / all age subheadings or explode ”Risk-for-Violence-Self-Directed-or-Directed-at-
Others-(NANDA)“/ all topical subheadings / all age subheadings or explode ”Crime“/ all topical subheadings / all age subheadingsv
or ”Masturbation“/ all topical subheadings / all age subheadings or ”Anger“/ all topical subheadings / all age subheadings or explode
”Weapons“/ all topical subheadings / all age subheadings or ”Prisoners“/ all topical subheadings / all age subheadings or ”Correctional-
Facilities“/ all topical subheadings / all age subheadings)
1.1.1.8 The Cochrane Controlled Trials Register (1999, Issue 4)
It was searched using the phrase:
75Droperidol for psychosis-induced aggression or agitation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near (kill or harm) or bodily near harm or
assault* or assail* or attacker* or physical near abus* or spouse near abus* or partner near abus* or child:ti near neglect:ti or child:ab
near neglect:ab or child:ti near abus*:ti child:ab near abus*:ab or elder near abus* or rape*:ti rape*:ab or rapist* or sexual*:ti near abus*:
ti or sexual*:ab near abus*:ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near public or
exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic*:ti malic*:ab or hostil*
or (dangerous or disrupt*) near (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near (behav* or histor*
or conduct*) or (antisocial or anti-social) near (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or
affray* or breach* near peace or felon* or unlawful* or penal* or penol* or crim*:ti crim*:ab or offen*:ti offen*:ab or prison* or inmate*
or correctional* or firearm* or weapon* or gun*:ti gun*:ab or agitat*) NOT (Cancer or carcinoma)
1.1.1.9 The Cochrane Schizophrenia Group’s Database of Conference Abstracts (1971 to December 1999)
It was searched using the phrase:
homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or assault* or assail* or attacker* or ((physical or spouse
or elder or sexual* or child or partner) and abus*) or rape* or rapist* or bugger* or sodom* or molest* or pedophil* or paedophil*
or indecen* or exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* or
hostil* or cruel* or delinquen* or threaten* or disorderly or affray* or felon* or unlawful* or penal* or penol* or crim* or offen* or
prison* or inmate* or correctional* or firearm* or weapon* or gun* or (intent and (kill or harm)) or (bodily and harm) or (child and
neglect) or masturbat* or (breach* and peace) or (dangerous and (behav* or histor* or conduct*)) or (disrupt* and (behav* or histor*
or conduct*)) or ((destruct* and not self-destruc*) and (behav* or histor* or conduct*)) or ((anti-social or antisocial) and (behav* or
histor* or conduct*)) or agitat*
1.1.1.10 The Cochrane Schizophrenia Group Register (updated June 2000)
It was searched using the phrase:
homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or ”intent to kill“ or ”intent to harm“ or ”bodily harm“
or assault* or assail* or attacker* or ”physical abus*“ or ”spouse abus*“ or ”partner abus*“ or ”child neglect“ or ”child abus*“ or ”elder
abus*“ or rape* or rapist* or ”sexual* abus*“ or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat*
or exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* or hostil* or
”(dangerous or disrupt*) near (behav* or histor* or conduct*)“or ”dangerousness or (destruct* not self-destruct*) near (behav* or histor*
or conduct*)“or ”(antisocial or anti-social) near (behav* or histor* or conduct*)“ or cruel* or delinquen* or threaten* or disorderly or
affray* or ”breach* of the peace“ or felon* or unlawful* or penal* or penol* or crim* or offen* or prison* or inmate* or correctional*
or firearm* or weapon* or gun* or agitat*
1.1.1.11 Criminal Justice Abstracts (January to September 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson)
1.1.1.12 Dissertations Abstracts (1861 to December 1999)
It was searched using the phrase:
(Homicid? or murder? or manslaughter? or infanticid? or parricid? or tortur? or (intent and (kill or harm)) or (bodily and harm) or
assault? or assail? or attacker? or physical abus? or spouse abus? or partner abus? or child neglect or child abus? or elder abus? or rape? or
rapist? or (sexual? and abus?) or bugger? or sodom? or molest? or pedophil? or paedophil? or indecen? or masturbat? or exhibitionis? or
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lewd? or sadis? or sadomasochis? or aggress? or violen? or anger or malic? or hostil? or cruel? or delinquen? or threaten? or disorderly or
affray? or (breach? and peace) or felon? or unlawful? or penal? or penol? or crim? or offen? or ((dangerous or disrupt?) or dangerousness
or (destruct? and not self-destruct?) or (antisocial or anti-social) or abduct? or kidnap? or prison? or inmate? or correctional? or firearm?
or weapon? or gun?) or agitat*) and (randomi? or (random? and assign?) or (random? and allocat?) or blind?)
1.1.1.13 Embase (1980 to October 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials (see Group Module) combined with
the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or
breach* near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison*
or inmate* or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or explode ”aggression“/
all subheadings or explode ”antisocial-behavior“/ all subheadings or ”pedophilia“/ all subheadings or ”offender“/ all subheadings or
”masturbation“/ all subheadings or ”exhibitionism“/ all subheadings or ”prison“/ all subheadings or ”prisoner“/ all subheadings or
”sadism“/ all subheadings or explode ”crime“/ all subheadings or explode ”weapon“/ all subheadings)
1.1.1.14 Health CD (1994 to December 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat*)
1.1.1.15 Index to Scientific and Technical Proceedings (1990 to March 2000)
It was searched using the phrase:
randomised or randomized or randomly & allocat* or randomly & assign* or doubl* & blind*
1.1.1.16 International Bibliography of the Social Sciences (1951 to January 2000)
It was searched using the phrase:
(random* alloc*) or randomi* or (random* assign*) or (double blind)
1.1.1.17 International Pharmaceutical Abstracts (1970 to December 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
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disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson)
1.1.1.18 MEDLINE (1966 to December 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or
breach* near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison*
or inmate* or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or explode ”Aggression“/
all subheadings or ”Sadism“/ all subheadings or ”Firearms“/ all subheadings or explode ”Anger“/ all subheadings or ”Dangerous-
Behavior“ or explode ”Homicide“/ all subheadings or explode ”Sex-Offenses“/ all subheadings or explode ”Violence“/ all subheadings
or ”Pedophilia“/ all subheadings or ”Masturbation“/ all subheadings or ”Exhibitionism“/ all subheadings or ”Prisoners“/ all subheadings
or explode ”Prisons“/ all subheadings” or Juvenile-Delinquency“/ all subheadings or ”Hostility“)
1.1.1.19 NCCAN
It was searched on the internet (http://www.CALIB.com/NCCANCH/ [Searched on December 14, 1999) using the phrase:
random or randomize or randomised or randomly
1.1.1.20 NCJRS
It was searched on the internet (http://www.NCJRS.org [Searched December 9, 1999] using the phrase:
randomi$ or (random$ and (alloc$ or assign$))
1.1.1.21 PAIS (1972 to October 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat*)
1.1.1.22 PASCAL (1984 to January 2000)
It was searched using the phrase:
(aggress* & randomi*) or (aggress* & randomly) or (violen* & randomi*) or (violen* & randomly) or (abus* & randomi*) or (abus*
& randomly)
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1.1.1.23 PsycLIT (1897 to September 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or explode ”Antisocial-Behavior“ or
explode ”Sadomasochism“ or ”Weapons-“ in DE or ”Prisoners-“ in DE or explode ”Anger“ or ”Penology-“ in DE or ”Exhibitionism-“
in DE or ”Aggressive-Behavior“ in DE or ”Aggressiveness-“ in DE or ”Dangerousness-“ in DE or explode ”Correctional-Institutions“
or explode ”Criminals“ or explode ”Homicide“ or ”Pedophilia-“ in DE or ”Masturbation-“ in DE)
1.1.1.24 Sociological Abstracts (1963 to September 1999)
It was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled trials combined with the phrase:
and (homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or intent near2 (kill or harm) or bodily near1 harm
or assault* or assail* or attacker* or physical abus* or spouse abus* or partner abus* or child neglect in ti or child neglect in ab or
child abus* in ti or child abus* in ab or elder abus* or rape* in ti or rape* in ab or rapist* or sexual* abus* in ti or sexual* abus* in
ab or bugger* or sodom* or molest* or pedophil* or paedophil* or indecen* or masturbat* near2 public or exhibitionis* or lewd* or
sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* in ti or malic* in ab or hostil* or (dangerous or
disrupt*) near2 (behav* or histor* or conduct*) or dangerousness or (destruct* not self-destruct*) near2 (behav* or histor* or conduct*)
or (antisocial or anti-social) near2 (behav* or histor* or conduct*) or cruel* or delinquen* or threaten* or disorderly or affray* or breach*
near3 peace or felon* or unlawful* or penal* or penol* or crim* in ti or crim* in ab or offen* in ti or offen* in ab or prison* or inmate*
or correctional* or firearm* or weapon* or (gun* in ti or gun* in ab) not gunderson or agitat* or ”Aggression-“ in DE or ”Violence-“ in
DE or ”Family-Violence“ in DE or explode ”Homicide“ or ”Kidnapping-“ in DE or ”Torture-“ in DE or explode ”Assault“ or ”Attack-
“ in DE or explode ”Child-Abuse“ or explode ”Elder-Abuse“ or explode ”Sexual-Abuse“ or explode ”Spouse-Abuse“ or ”Abuse-“ in
DE or ”Child-Neglect“ in DE or explode ”Offenders“ or ”Masturbation-“ in DE or explode ”Sexual-Deviation“ or explode ”Anger“
or ”Deviant-Behavior“ in DE or ”Threat-“ in DE or explode ”Criminality“ or ”Correctional-System“ in DE or explode ”Crime“ or
”Prisoners-“ in DE or ”Imprisonment-“ in DE or ”Juvenile-Correctional-Institutions“ in DE or ”Firearms-“ in DE)
1.1.1.25 SPECTR (ERIC, 1966 to 1998; Criminal Justice Abstracts, 1968 to 1998; Sociological Abstracts, 1974 to 1996)
It was searched using the phrase:
homicid* or murder* or manslaughter* or infanticid* or parricid* or tortur* or assault* or assail* or attacker* or ((physical or spouse
or elder or sexual* or child or partner) and abus*) or rape* or rapist* or bugger* or sodom* or molest* or pedophil* or paedophil*
or indecen* or exhibitionis* or lewd* or sadis* or sadomasochis* or abduct* or kidnap* or aggress* or violen* or anger or malic* or
hostil* or cruel* or delinquen* or threaten* or disorderly or affray* or felon* or unlawful* or penal* or penol* or crim* or offen* or
prison* or inmate* or correctional* or firearm* or weapon* or gun* or (intent and (kill or harm)) or (bodily and harm) or (child and
neglect) or masturbat* or (breach* and peace) or (dangerous and (behav* or histor* or conduct*)) or (disrupt* and (behav* or histor*
or conduct*)) or ((destruct* and not self-destruc*) and (behav* or histor* or conduct*)) or ((anti-social or antisocial) and (behav* or
histor* or conduct*)) or agitat*
1.1.1.26 The Composite Aggression/Violence Trials Database
Searches 1.1 to 1.25 identified some 22,000 references of which 2,200 appeared to be randomised controlled trials relevant to the
management of aggressive or violent people. This database was searched using the following phrase:
Droperidol* OR Inapsin* OR Droleptan OR dehydrobenzperidol OR Dridol OR Sintodian OR Paxical OR (Leptanal AND comp*)
OR Leptofen OR r04749*
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1.1.2 Searching other resources
1.1.2.1 Reference searching
We inspected references of all included studies for further relevant studies.
1.1.2.2 Personal contact
We contacted the first author of each included study for information regarding unpublished trials.
1.2 Search in 2013
1.2.1 Electronic searches
1.2.1.1 Cochrane Schizophrenia Group’s Register
We searched Cochrane Schizophrenia Group’s Register (August 12, 2013) using the phrase:
(droperidol* or *4749* orDehydrobenzperidol* orDridol* orDroleptan* or Inapsin* or Leptanal* or Leptofen* or Paxical* or Sintodian*
or Thalamonal* in title) or (*droperidol* or *4749* or *Dehydrobenzperidol* or *Dridol* or *Droleptan* or *Inapsin* or *Leptanal*
or *Leptofen* or *Paxical* or *Sintodian* or *Thalamonal* in abstract, index or title terms of REFERENCE) or droperidol* or *4749*
or Dehydrobenzperidol* or Dridol* or Droleptan* or Inapsin* or Leptanal* or Leptofen* or Paxical* or Sintodian* or Thalamonal* in
interventions of STUDY }
The Schizophrenia Group’s trials register is based on regular searches of BIOSIS Inside, CENTRAL, CAJ, CINAHL, EMBASE,
MEDLINE and PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey
literature sources. A full description is given in the Group’s module.
Appendix 2. Previous data collection and analysis
We (MM and AL) searched The Cochrane Schizophrenia Group’s register. Working independently we examined the papers identified
from the search strategy.We discarded obviously irrelevant publications and retained only those in which some form of early intervention
had been compared against a control treatment, and obtained copies of papers relating to relevant trials. Once we had obtained these
papers, we decided whether the trials were eligible. We resolved any disagreements by discussion. For the 2006 update we (MM and JR)
independently inspected citations. Where disagreement occurred, we sought to resolve this by discussion, or where doubt remained, we
acquired the full article for further inspection. Once we had obtained the full articles, we independently decided whether they met the
review criteria. We resolved any disagreements that occurred by discussion, and when this was not possible we added trials to the list of
those awaiting assessment until we acquired further information. For the 2009 update we (MM and JR) inspected all study citations
identified by the searches, and obtained full reports of the studies of agreed relevance.
Data extraction and management
1. Extraction
We (MM, AL) independently extracted and entered trial data into Review Manager (RevMan) twice, cross-checking for consistency (
RevMan 2008). An initial analysis included all trials meeting inclusion criteria, whilst a second sensitivity analysis excluded all but the
highest quality trials (Category A and B). For the 2006 and 2010 update, we (MM and JR) independently extracted and entered data
into RevMan, cross-checking again for consistency. Where disputes arose, we attempted to resolve these by discussion. When this was
not possible and further information was needed to resolve the dilemma, we did not enter the data, and added this outcome of the trial
to the list of those awaiting assessment.
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2. Management
2.1 Forms
We extracted the data onto standard, simple forms.
2.2 Direction of graphs
Where possible, we entered data into RevMan in such a way that the area to the left of the ’line of no effect’ indicates a ’favourable’
outcome for early intervention. Where this was not possible, (for example, scales that calculate higher scores=improvement) we inserted
a minus sign into the data tables to reverse the graphical display in RevMan analyses so that the direction of effect was clear.
2.3 Scale-derived data
Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (Marshall 2000). Therefore we only included
continuous data from rating scales were if the measuring instrument had been described in a peer-reviewed journal.
2.4 Skewed data
Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of
applying parametric tests to non-parametric data we applied the following standards to continuous final value endpoint data before
inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started
from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise the mean is unlikely to be an
appropriate measure of the centre of the distribution - Altman 1996); in cases with data that are greater than the mean we entered
them into the ’Other data’ table as skewed data. Where the skewed data are derived from a trial with
>
= 200 participants, the skewed
data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.
If a scale starts from a positive value (such as PANSS, which can have values from 30 to 210) the calculation described above in (b)
should be modified to take the scale starting point into account. In these cases skewness is present if 2SD>(S-Smin), where S is the
mean score and Smin is the minimum score. We reported non-normally distributed data (skewed) in the ’other data types’ tables.
For change data (mean change from baseline on a rating scale) it is impossible to tell whether data are non-normally distributed (skewed)
or not, unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we entered change
data in RevMan analyses and reported the finding in the text to summarise available information. In doing this, we assumed either that
data were not skewed or that the analysis could cope with the unknown degree of skew.
2.5 Final endpoint value versus change data
Where both final endpoint data and change data were available for the same outcome category, only final endpoint data were presented.
We acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data is more clinically
relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. Where
studies reported only change data we contacted authors for endpoint figures.
2.6 Common measure
To facilitate comparison between trials, we converted variables (such as days in hospital) that could be reported in different metrics
(mean days per year, per week or per month) to a common metric (for example, mean days per month).
2.7 Conversion of continuous to binary
Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clinically improved’ or ’not clinically improved’. It was generally assumed
that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the
Positive and Negative Syndrome Scale (PANSS, Kay 1986), this could be considered as a clinically significant response (Leucht 2005a;
Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.
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2.8 Summary of findings table
For the 2011 version of the review we had available to us the possibility of producing Summary of Findings tables. These should be
considered before being biased by the results of analyses, but for us this is impossible. We have chosen to present two - but this choice is
post hoc. We chose to present data from PACE-Australia and OPUS-Scandinavia as these are benchmark trials in this area and outcomes
from these trials that we think to be clinically important.
• Progression to psychosis
• Compliance with treatment - treatment stopped in spite of need
• Leaving the study early
• Service use: 1. Average mean number of days per month in hospital
• Service use: 2. Not hospitalised
• Social outcomes: 1. Not living independently
• Social outcomes: 2. Not working or in education
Assessment of risk of bias in included studies
Again working independently, we assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2008). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the
integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included
studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.
The categories are defined below.
- YES - low risk of bias
- NO - high risk of bias
- UNCLEAR - uncertain risk of bias
If disputes arose as to which category we should allocate a trial, again, we achieved resolution by discussion, after working with a third
reviewer.
Earlier versions of this review used a different, less well-developed, means of categorising risk of bias (see Appendix 2).
Measures of treatment effect
1. Binary data
For binary outcomes we calculated an estimate of the risk ratio (RR) and its 95% (fixed-effect) confidence intervals (CI). RR is more
intuitive (Boissel 1999) than odds ratios and odds ratios tend to be interpreted as RR by clinicians (Deeks 2000). This misinterpretation
then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed
to treat/harm (NNT/NNH) using Visual Rx.
2. Continuous data
For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures
(standardised mean difference SMD). However, had scales of very considerable similarity been used, we would have presumed there
was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or
more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice), but analysis and pooling of clustered
data pose problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a unit-of-analysis
error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes Type I errors (Bland 1997; Gulliford 1999).
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Where clustering had not been accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the
presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to
obtain intra-class correlation co-efficients (ICCs) of their clustered data and to adjust for this using accepted methods (Gulliford 1999).
Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster
randomised study, but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect.
This is calculated using the mean number of participants per cluster (M) and the ICC (Design effect=1+ (M -1)*ICC) (Donner 2002).
If the ICC is not reported we assumed it to be 0.1 (Ukoumunne 1999). If cluster studies had been appropriately analysed taking into
account ICCs and relevant data documented in the report, we synthesised these¬with other studies using the generic inverse variance
technique.
2. Cross-over design
A major concern of cross-over trials is the carry-over effect. It occurs if an effect (for example, pharmacological, physiological or
psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state, despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in schizophrenia,¬we will only
use¬data¬of the first phase of cross-over studies.
3. Studies with multiple treatment groups
We presented studies involving more than two treatment arms, if relevant, in comparisons.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss to follow-up data must lose credibility (Xia 2007). We are forced to make a judgment where this is for the trials
likely to be included in this review. Should more than 50% of data be unaccounted for by eight weeks, we did not reproduce these data
or use them within analyses.
2. Intention to treat analysis
2.1 Binary data
We excluded data from studies where more than 50% of participants in any group were lost to follow-up (this did not include the
outcome of ’leaving the study early’). In studies with less than 50% dropout rate, people leaving early were considered to have had
the negative outcome, For example, those lost to follow-up for the outcome of relapse were treated in the analysis as having relapsed.
Suicide was treated as relapse.
2.2 Continuous data
2.2.1 Attrition
In the case where attrition for a continuous outcome is between 0% and 50% and completer-only data were reported, we have
reproduced these.
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2.2.2 Standard deviations
Wefirst tried to obtain themissing values from the authors. If not available, where there weremissingmeasures of variance for continuous
data but an exact standard error and confidence interval were available for group means, and either P value or T value were available
for differences in mean, we noted these, and in future versions will calculate them according to the rules described in the Handbook
(Higgins 2008): When only the standard error (SE) is reported, standard deviations (SDs) can be calculated by the formula SD=SE
* square root (n). Chapters 7.7.3 and 16.1.3 of the Handbook (Higgins 2008) present detailed formula for estimating SDs from P
values, T or F values, confidence intervals, ranges or other statistics. If these formula do not apply, we, in the future will calculate SDs
according to a validated imputation method which is based on the SDs of the other included studies (Furukawa 2006). Some of these
imputation strategies can introduce error. The alternative would be to exclude a given study’s outcome and thus to lose information.
We will examine the validity of the imputations in a sensitivity analysis excluding imputed values.
2.2.3 Last observation carried forward
We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results.
Therefore, where LOCF data have been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and
indicated that they are the product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all
studies for clearly outlying situations or people which we had not predicted would arise. When such situations or participant groups
arose, we would have fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judgemethodological heterogeneity.We simply inspected
all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers arise we would
have fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the I2 method alongside the Chi2 P value. The I2 provides an estimate of
the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I2 depends on i.
magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi2¬test, or a confidence interval
for I2). We interpreted I2 estimate greater than or equal to 50% accompanied by a statistically significant Chi2 statistic as evidence of
substantial levels of heterogeneity (Section 9.5.2 - Higgins 2008). When substantial levels of heterogeneity were found in the primary
outcome, we explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).
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Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are
described in section 10.1 of the Handbook (Higgins 2006). We are aware that funnel plots may be useful in investigating reporting
biases but are of limited power to detect small-study effects (Egger 1997). We did not use funnel plots for outcomes where there were
10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical
advice in their interpretation.
Data synthesis
Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of
fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating
different, yet related, intervention effects. This does seem true to us; however, random-effects does put added weight onto the smaller
of the studies - those trials that are most vulnerable to bias. For this reason we favour using the fixed-effect model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We did not anticipate subgroup analyses.
2. Investigation of heterogeneity
If inconsistency was high, we have reported this. First we investigated whether data had been entered correctly. Second, if data had
been correct, we visually inspected the graph and successively removed studies outside of the company of the rest to see if homogeneity
was restored. Should this occur with no more than 10% of the data being excluded, we have presented data. If not, we have not pooled
data and have discussed relevant issues.
Should unanticipated clinical or methodological heterogeneity be obvious we simply stated hypotheses regarding these for future reviews
or versions of this review. We did not anticipate undertaking analyses relating to these.
Sensitivity analysis
For the 2011 version of this review we did not anticipate undertaking any additional sensitivity analyses.
Appendix 3. Previous effects of interventions
1. Comparison 1. droperidol versus placebo
The search identified only one small (N = 41) randomised trial comparing droperidol (10 mg IV) with placebo (IV) Van Leeuwen
1977a.
1.1 Global impression: needing additional injections within the first 90 minutes.
Those allocated to droperidol were significantly less likely to need additional haloperidol injections within the first few minutes (N =
41, RR 0.37, 95% CI 0.2 to 0.7, NNTB 2, 95% CI 1 to 10) than those given an injection of placebo. By 90 minutes, this difference
was still evident but not statistically significant (RR 0.46, 95% CI 0.2 to 1.2).
1.2 Adverse effects
The Van Leeuwen 1977a trial reported that no adverse effects were apparent for the 41 people randomised to droperidol or placebo.
However, this observation referred only to the first threeminutes after the initial injection had been given. After threeminutes haloperidol
was administered to 25/41 trial participants and some adverse effects may have been caused by that drug. However, any that occurred
after the first three minutes were not reported.
2. Comparison 2. droperidol versus haloperidol
The search identified only two small trials. Resnick 1984 (N = 27) was clearly relevant to the acute management of disturbed people. In
this study, participants were randomised to 5 mg of IM droperidol or 5mg of IM haloperidol. Cocchi 1971, however, was also identified
by the search and is less clearly relevant. Although this study does deal with acutely disturbed or relapsing people, it allocated them to
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oral droperidol or haloperidol, suggesting that these trial participants were not as disturbed as in the other studies. Outcomes were also
measured after 30 days rather than after a few hours, which makes this trial less relevant to the emergency situation investigated by this
review.
2.1 Global impression: needing additional injections within the first 90 minutes
Those allocated to droperidol were less likely to need additional injections by 30 minutes than those given haloperidol, but this result
did not quite reach conventional levels of statistical significance (N = 27, 1 RCT, RR 0.45, 95% CI 0.2 to 1.0). Resnick 1984 reported
the need for additional repeat injections up to 90 minutes. Not one of those allocated to droperidol required repeat injections, but three
in the haloperidol group were given another injection at 60 minutes (N = 27, RR 0.20, 95% CI 0.01 to 3.6), and one unfortunate
person had to be medicated yet again at 90 minutes (N = 27, 1 RCT, RR 0.47, 95% CI 0.02 to 10.6).
2.2 Global impression: no clear improvement by 30 days
Cocchi 1971 reported that oral droperidol was no more likely to afford improvement in acutely ill people than oral haloperidol at 30
days (N = 40, RR 0.67, 95% CI 0.3 to 1.5).
2.3 Mental state: mean score on the Rating Scale for Quantification of Psychotic Symptoms
The study on less acutely disturbed people in the non-emergency situation found no difference between oral droperidol and oral
haloperidol on ratings of this scale (N = 40, mean difference 0.11, 95% CI -0.1 to 0.3) (Cocchi 1971).
2.4 Adverse effects: mild dystonia
Resnick 1984 reported that one person experienced a mild dystonic reaction when given haloperidol IM (N = 27, RR 0.47, 95% CI
0.02 to 10.6).
Appendix 4. Previous discussion
1. Droperidol discontinued
Janssen-Cilag Limited produced droperidol (www. janssen-cilag.co.uk) until March 2001, when production of all formulations of its
branded form (Droleptan) were discontinued. TheMedicines Control Agency in the UK (www.mca.gov.uk/) had raised concerns about
the potential effects of long-term droperidol on the electrical conduction of the heart (cardiac Q-T interval prolongation) and requested
a risk-benefit assessment. The company concluded that the oral formulations should be discontinued to prevent use. The authors have
asked Janssen-Cilag UK whether or not the injectable form for rapid tranquillisation was withdrawn because of concerns about safety.
The company have informed us that the injectable form of droperidol also carries significant risks (Lawrence 1997) and has been
associated with prolonged Q-T intervals (Guy 1991; Lischke 1994) as well as the rare, but potentially fatal, cardiac arrhythmia, ’Torsade
de pointes’ (Guy 1991; Michalets 1998). Although the benefits of its continued use in the acute situation may have outweighed these
risks, careful monitoring - including ECGs and electrolyte assays - would have been necessary. This would have compromised the cost
effective production of injectable droperidol, and so it was discontinued along with the oral preparations.
2. Small number of studies
Acute psychosis is difficult to study and co-operation from the study population is rare. This may be one of the reasons for the scarcity
of controlled clinical trials using droperidol solely for this indication. Droperidol appears to have been widely used in emergency room
situations for people who are agitated or acutely disturbed but who have not, at point of medication, been diagnosed (Binder 1999;
Pilowsky 1992). Several papers identified by our searches concerned the use of droperidol for people who were later diagnosed as
having either trauma, an underlying organic condition, or who were intoxicated. As these diagnoses fell outside our remit for types of
participants, the trials were excluded from this review. Nevertheless, acute disturbance due to suspected mental illness is so common
(Huf 2002), and management of such situations so important, that there is little excuse not to have good evidence for the use of
droperidol. However, a total of only 69 people seem to have been randomised into trials of droperidol versus placebo or haloperidol
that are relevant to the emergency control of disturbance thought to be due to mental illnesses.
3. Quality
No trial reported adequate methods of random sequence generation, and only Van Leeuwen 1977a included any description of the
method of randomisation. No trial included in this review would have rated highly with respect to the CONSORT statement (Begg
1996; Moher 2001) and the inclusion of bias is likely.
4. Publication bias
With such small studies publication bias is also likely, and for both truly relevant trials (Resnick 1984; Van Leeuwen 1977) droperidol
was the experimental intervention, so any publication bias would favour droperidol.
5. Applicability of findings
The included trials were set in a psychiatric hospital, an emergency department, and a psychiatric crisis unit. The truly relevant studies
(Resnick 1984; Van Leeuwen 1977) reported outcomes for the very short term, i. e. those of value in the crisis situation. Van Leeuwen
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1977a included people with schizophrenia, manic-depression and confusional states, with seven of the 41 participants having no
diagnosis recorded. Resnick 1984 included participants who were involuntarily hospitalised and had ’underlying psychoses’. This trial
specifically excluded patients who were intoxicated (the only trial to specifically mention exclusion criteria). These inclusion criteria
should make any findings applicable to the acute management of disturbed people thought to suffer from serious mental illnesses.
However, although need for repeat injection is of importance, it would also have been desirable to have had outcomes such as further
aggressive episodes, tranquillisation, sedation and carer satisfaction.
5. Comparison 1. droperidol versus placebo
The small amount of data available (N = 41) suggests that droperidol is superior to placebo three minutes after injection (fewer repeat
injections needed). However, the design of this study precluded good information about adverse effects, and, while such limited data
could generate hypotheses, it does not provide conclusive evidence.
6. Comparison 2. droperidol versus haloperidol
Although the search identified two trials, only Resnick 1984 (N = 27) was clearly relevant to the acute management of disturbed people.
Cocchi 1971 did not assess the immediate effects of droperidol given as emergency medication, but compared it to haloperidol in a
study of 30 days’ duration. Droperidol was not statistically different to haloperidol for the proportion of participants needing additional
injections at 30 minutes, but this difference would be clinically relevant if sustained in larger studies (~40% droperidol versus ~60%
haloperidol). Haloperidol did cause a mild dystonic reaction in one person. The results of Resnick 1984 indicate that droperidol is a
valuable drug in the acute situation, but, were it still being used, all findings would need to be replicated.
7. Heterogeneity
This review is a re-presentation of the findings of trials rather than a meta-analysis in which heterogeneity could operate.
8. Sensitivity analysis
It had been hoped to conduct sensitivity analyses comparing results when trials with high attrition with those with only competer data.
All three trials reported on loss to follow up and this was not undertaken.
F E E D B A C K
Error in publication date of van Leeuwen study, 14 May 2008
Summary
I would like to advise of an error in the date of one of the studies included. Reference by van Leeuwen was published in 1977 not 1997?
(1997 was used in various sites of the paper).
Reply
We thanked the contributor for alerting the review authors to this error and have now made the necessary amendments to the review.
Contributors
Feedback submitted by Esther Chan.
Reply submitted by Bethany York, Review Group Co-ordinator, Cochrane Schizophrenia Group.
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WH A T ’ S N E W
Last assessed as up-to-date: 13 January 2016.
Date Event Description
1 June 2016 New citation required but conclusions have not changed New evidence added to review but conclusions un-
changed
13 January 2016 New search has been performed Major update. Two new trials added. Conclusions un-
changed but strengthened
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2001
Date Event Description
13 November 2013 Amended Eight new references from updated search (August 12,
2013) were added to ’Pending classification references’
section of the review
3 May 2012 Amended Additional table linked to text
13 April 2011 Amended Contact details updated.
20 April 2009 Feedback has been incorporated Further to submitted feedback the publication date of
the van Leeuwen study has been corrected from 1997
to 1977
24 April 2008 Amended Converted to new review format.
18 September 2003 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Mariam A. Khokhar (update 2016): primary review author, results and discussion writing.
John Rathbone (2011): study selection, data extraction, writing review.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Academic Unit of Psychiatry, University of Leeds, UK.
• Said Business School, University of Oxford, UK.
External sources
• NHS National R&D Programme on Forensic Mental Health, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added further details in the background information slightly to reflect more recent literature.
We amended some of the outcomes between the protocol and this update to reflect Cochrane Schizophrenia Group presentation
and wording of outcomes, the type of outcomes remains the same.We have grouped primary outcomes under three main outcomes:
tranquil or asleep by up to 30 minutes, another episode of aggression by 24 hours, and specific and serious adverse effects by 24 hours.
The secondary outcomes are under 11 main headings: tranquillisation or asleep, specific behaviours, global state, service outcomes,
mental state, adverse effects, leaving the study early, satisfaction with treatment, acceptance of treatment, quality of life and economic
outcomes. We felt in retrospect that these outcomes were important given the persistent and all-encompassing nature of schizophrenia.
As no relapse data were available, we did not present ’relapse’ data in the ’Summary of findings’ tables, presenting ’leaving the study
early’ data instead.
We have also slightly widened our inclusion criteria by including studies where the majority of people in the study had some form
of mental illness that was thought to be fuelling their aggression/agitation - even if their data were ’contaminated’ by data relating to
people who were aggressive for reasons thought to not be because of mental illness.
We have updated themethods section with the latest template provided by theCochrane SchizophreniaGroup (see Acknowledgements).
N O T E S
None.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Acute Disease; Aggression [drug effects]; Antipsychotic Agents [∗therapeutic use]; Benzodiazepines [therapeutic use]; Droperidol
[∗therapeutic use]; Haloperidol [therapeutic use]; Midazolam [therapeutic use]; Psychomotor Agitation [drug therapy]; Psychotic
Disorders [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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